Patent application title: DEVELOPMENTS IN MENINGOCOCCAL OUTER MEMBRANE VESICLES
Inventors:
IPC8 Class: AA61K39095FI
USPC Class:
1 1
Class name:
Publication date: 2019-06-20
Patent application number: 20190183999
Abstract:
A first aspect of the invention provides meningococcal outer membrane
vesicles in which NHBA is over-expressed. A second aspect of the
invention provides meningococcal outer membrane vesicles in which NadA is
over-expressed. A third aspect of the invention provides a panel of
bacterial strains, each member of which is isogenic except for a single
gene which in each strain encodes a different variant antigen of
interest.Claims:
1. Meningococcal outer membrane vesicles in which NHBA is over-expressed.
2. A meningococcus which over-expresses NHBA.
3. The meningococcus of claim 2, which also over-expresses fHbp.
4. A meningococcus which expresses NHBA, wherein the meningococcus is isogenic with a parental strain, except for a genetic modification which causes the meningococcus to express more NHBA than the parental strain.
5. The meningococcus of claim 4, which includes (i) a gene under the control of a promoter which does not control that gene in the parental strain and/or (ii) a knockout of a gene which is found in the parental strain.
6. The meningococcus of claim 2, wherein expression of NHBA is controlled by an inducible or constitutive promoter, and wherein the promoter optionally includes a CREN.
7. The meningococcus of claim 2, wherein the meningococcus does not express NadR.
8. The meningococcus of claim 2, wherein the bacterium also expresses more fHbp than the parental strain.
9. The meningococcus of claim 2, wherein expression of NHBA is controlled by a strong promoter, NadR is knocked out, and the strain expresses a constitutively active mutant FNR.
10. The meningococcus of claim 2, wherein expression of NHBA is controlled by a strong promoter, expression of fHbp is controlled by a strong promoter, and NadR is knocked out.
11. The meningococcus of claim 2, wherein the bacterium has a knockout of LpxL1.
12. The meningococcus of claim 2, wherein the bacterium does not express an active MltA.
13. The meningococcus of claim 2, wherein the bacterium does not express PorA.
14. The meningococcus of claim 2, wherein the bacterium does not express FrpB.
15. The meningococcus of claim 2, in serogroup B.
16. The meningococcus of claim 2, in immunotype L3.
17. Outer membrane vesicles prepared from the meningococcus of claim 2.
18. A process for preparing a meningococcal strain suitable for OMV preparation, comprising steps of (i) choosing a starting strain which expresses NHBA; and (ii) modifying the starting strain to increase the amount of NHBA which it expresses.
19. A process for preparing a meningococcal strain suitable for OMV preparation, comprising steps of (i) choosing a starting strain which expresses a first amount of NHBA when grown in specific culture conditions, then (ii) modifying the starting strain to provide a modified strain, wherein the modified strain expresses a second amount of NHBA when grown in the same specific culture conditions, wherein the second amount is higher than the first amount.
20. The process of claim 18, including a step (iii) culturing the modified bacteria obtained in step (ii) to provide a bacterial culture.
21. (canceled)
22. A process for preparing a meningococcal vesicle, comprising a step of treating a bacterial culture obtained by the process of claim 20 such that its outer membrane forms vesicles.
23. Outer membrane vesicles prepared by the process of claim 22.
24. An immunogenic pharmaceutical composition comprising the vesicles of claim 1.
25. The composition of claim 24, including one or more capsular saccharides from meningococci.
26. The composition of claim 24, including an antigen from Streptococcus pneumoniae.
27. A method for raising an immune response in a mammal, comprising administering a composition of claim 24 to the mammal.
Description:
SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE
[0001] The content of the following submission on ASCII text file is incorporated herein by reference in entirety: a computer readable form (CRF) of the Sequence Listing (file name: 303822003801SeqList.txt, date recorded: Dec. 20, 2015, size: 102 KB).
FIELD OF THE INVENTION
[0002] This invention is in the field of meningococcal vaccines based on membrane vesicles.
BACKGROUND ART
[0003] Various vaccines against serogroup B of Neisseria meningitidis ("MenB") are currently being investigated. Some of these are based on outer membrane vehicles (OMVs), such as the Novartis MENZB.TM. product, the Finlay Institute VA-MENGOC-BC.TM. product, and the Norwegian Institute of Public Health MENBVAC.TM. product. Reference 1 discloses the construction of vesicles from strains modified to express six different PorA subtypes. References 2-4 report pre-clinical studies of an OMV vaccine in which fHbp (also known as GN1870) is over-expressed (and this over-expression can be combined with knockout of LpxL1 [5]). Reference 6 recently reported a clinical study of five formulations of an OMV vaccine in which PorA & FrpB are knocked-out and Hsf & TbpA are over-expressed. Reference 7 reports a native outer membrane vesicle vaccine prepared from bacteria having inactivated synX, lpxL1, and 1gtA genes.
[0004] It is an object of the invention to provide further and improved meningococcal OMVs, and also to provide further and improved meningococci for use in vaccine production.
DISCLOSURE OF THE INVENTION
[0005] A first aspect of the invention provides meningococcal outer membrane vesicles in which NHBA is over-expressed. A second aspect of the invention provides meningococcal outer membrane vesicles in which NadA is over-expressed. A third aspect of the invention provides a panel of bacterial strains, each member of which is isogenic except for a single gene which in each strain encodes a different variant of an antigen of interest.
Over-Expression
[0006] The first and second aspects of the invention provide meningococcal outer membrane vesicles in which certain antigens are over-expressed. In the first aspect, at least NHBA is over-expressed. In the second aspect, at least NadA is over-expressed.
[0007] As discussed below, these vesicles are obtained from bacteria which over-express the relevant antigen(s). The bacterium may express the antigen(s) already, but include a genetic modification which, compared to a bacterium without that modification, increases expression of the antigen. This modification will usually be introduced using recombinant techniques, such as site-directed mutagenesis or targeted homologous recombination, so vesicles of the invention are usually obtained from recombinant bacteria. Typically a bacterium will include (i) a gene under the control of a promoter with which it is not found in nature and/or (ii) a knockout of a gene which is found in the bacterium in nature.
[0008] As a result of the over-expression, outer membrane vesicles prepared from the modified meningococcus contain higher levels of the over-expressed antigen(s). The increase in expression in the OMVs is usefully at least 10%, measured in mass of the relevant antigen per unit mass of OMV, and is more usefully at least 20%, 30%, 40%, 50%, 75%, 100% or more.
[0009] Suitable recombinant modifications which can be used to cause over-expression of an antigen include, but are not limited to: (i) promoter replacement; (ii) gene addition; (iii) gene replacement; or (iv) repressor knockout.
[0010] In promoter replacement, the promoter which controls expression of the antigen's gene in a bacterium is replaced with a promoter which provides higher levels of expression. For instance, the gene might be placed under the control of a promoter from a housekeeping metabolic gene. In other embodiments, the antigen's gene is placed under the control of a constitutive or inducible promoter. Similarly, the gene can be modified to ensure that its expression is not subject to phase variation. Methods for reducing or eliminating phase variability of gene expression in meningococcus are disclosed in reference 8. These methods include promoter replacement, or the removal or replacement of a DNA motif which is responsible for a gene's phase variability.
[0011] In gene addition, a bacterium which already expresses the antigen receives a second copy of the relevant gene. This second copy can be integrated into the bacterial chromosome or can be on an episomal element such as a plasmid. The second copy can have a stronger promoter than the existing copy. The gene can be placed under the control of a constitutive or inducible promoter. The effect of the gene addition is to increase the amount of expressed antigen. Where a plasmid is used, it is ideally a plasmid with a high copy number e.g. above 10, or even above 100.
[0012] In gene replacement, gene addition occurs but is accompanied by deletion of the existing copy of the gene. For instance, this approach was used in reference 4, where a bacterium's endogenous chromosomal fHbp gene was deleted and replaced by a plasmid-encoded copy (see also reference 9). Expression from the replacement copy is higher than from the previous copy, thus leading to over-expression.
[0013] In repressor knockout, a protein which represses expression of an antigen of interest is knocked out. Thus the repression does not occur and the antigen of interest can be expressed at a higher level.
[0014] Promoters for over-expressed genes can advantageously include a CREN [10].
[0015] A over-expressing modified strain will generally be isogenic with its parent strain, except for a genetic modification. As a result of the modification, expression of the antigen of interest in the modified strain is higher (under the same conditions) than in the parent strain. A typical modification will be to place a gene under the control of a promoter with which it is not found in nature and/or to knockout a gene which encodes a repressor.
[0016] In embodiments where NHBA is over-expressed, various approaches can be used. For convenience, the approach already reported in reference 11 can be used i.e. introduction of a NHBA gene under the control of an IPTG-inducible promoter. By this approach the level of expression of NHBA can be proportional to the concentration of IPTG added to a culture. The promoter may include a CREN.
[0017] In embodiments where NadA is over-expressed, various approaches can be used. One useful approach involves deletion of the gene encoding NadR (NMB1843), which is a transcriptional repressor protein [12] which down-regulates or represses the NadA-encoding gene in all strains tested. Knockout of NadR results in high-level constitutive expression of NadA. An alternative approach to achieve NadA over-expression is to add 4-hydroxyphenylacetic to the culture medium. A further approach is to introduce a NadA gene under the control of an IPTG-inducible promoter.
[0018] In some embodiments a bacterium over-expresses both NHBA and NadA.
[0019] In addition to over-expressing NHBA and/or NadA, a bacterium may over-express one or more further antigens. For instance, a bacterium may over-express one or more of: (a) NhhA; (b) TbpA; (c) HmbR; (d) TbpB; (e) NspA; (f) Cu,Zn-superoxide dismutase; (g) Omp85; (h) App; and/or (i) fHbp. Over-expression of NhhA is already reported in references 6 and 13. Over-expression of TbpA is already reported in references 6, 13 and 14. Over-expression of HmbR is already reported in reference 15. Over-expression of TbpB is already reported in reference 14. Over-expression of NspA is already reported in reference 16, in combination with porA and cps knockout. Over-expression of Cu,Zn-superoxide dismutase is already reported in reference 14. Over-expression of fHbp is already reported in references 2-4 & 9, and by a different approach (expressing a constitutively-active mutant FNR) in references 17 & 18.
[0020] In some embodiments a bacterium over-expresses NHBA, NadA and fHbp. These three antigens are components of the "universal vaccine" disclosed in reference 19 or "4CMenB" [20, 21]. In one embodiment, expression of NHBA is controlled by a strong promoter, NadR is knocked out, and the strain expresses a constitutively active mutant FNR. In another embodiment, expression of NHBA is controlled by a strong promoter, expression of fHbp is controlled by a strong promoter, and NadR is knocked out. The bacterium can also be a bacterium which does not express an active MltA (GNA33), such that it spontaneously releases vesicles which contain NHBA, NadA and fHbp. Ideally, the bacterium does not express a native LPS e.g. it has a mutant or knockout of LpxL1.
Vesicles
[0021] The first and second aspects of the invention provide meningococcal outer membrane vesicles. These outer membrane vesicles include any proteoliposomic vesicle obtained by disruption of or blebbling from a meningococcal outer membrane to form vesicles therefrom that retain antigens from the outer membrane. Thus the term includes, for instance, OMVs (sometimes referred to as `blebs`), microvesicles (MVs [22]) and `native OMVs` (`NOMVs` [23]).
[0022] MVs and NOMVs are naturally-occurring membrane vesicles that form spontaneously during bacterial growth and are released into culture medium. MVs can be obtained by culturing Neisseria in broth culture medium, separating whole cells from the smaller MVs in the broth culture medium (e.g. by filtration or by low-speed centrifugation to pellet only the cells and not the smaller vesicles), and then collecting the MVs from the cell-depleted medium (e.g. by filtration, by differential precipitation or aggregation of MVs, by high-speed centrifugation to pellet the MVs). Strains for use in production of MVs can generally be selected on the basis of the amount of MVs produced in culture e.g. refs. 24 & 25 describe Neisseria with high MV production.
[0023] OMVs are prepared artificially from bacteria, and may be prepared using detergent treatment (e.g. with deoxycholate), or by non-detergent means (e.g. see reference 26). Techniques for forming OMVs include treating bacteria with a bile acid salt detergent (e.g. salts of lithocholic acid, chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, cholic acid, ursocholic acid, etc., with sodium deoxycholate [27 & 28] being preferred for treating Neisseria) at a pH sufficiently high not to precipitate the detergent [29]. Other techniques may be performed substantially in the absence of detergent [26] using techniques such as sonication, homogenisation, microfluidisation, cavitation, osmotic shock, grinding, French press, blending, etc. Methods using no or low detergent can retain useful antigens such as NspA [26]. Thus a method may use an OMV extraction buffer with about 0.5% deoxycholate or lower e.g. about 0.2%, about 0.1%, <0.05% or zero.
[0024] A useful process for OMV preparation is described in reference 30 and involves ultrafiltration on crude OMVs, rather than instead of high speed centrifugation. The process may involve a step of ultracentrifugation after the ultrafiltration takes place.
[0025] Another useful process for outer membrane vesicle production is to inactivate the mltA gene in a meningococcus, as disclosed in reference 31. These mutant bacteria spontaneously release vesicles into their culture medium.
[0026] If lipo-oligosaccharide (LOS) is present in a vesicle it is possible to treat the vesicle so as to link its LOS and protein components ("intra-bleb" conjugation [43]).
[0027] The vesicles may lack LOS altogether, or they may lack hexa-acylated LOS e.g. LOS in the vesciles may have a reduced number of secondary acyl chains per LOS molecule [32]. For example, the vesicles may from a strain which has a lpxL1 deletion or mutation which results in production of a penta-acylated LOS [3, 7]. LOS in a strain may lack a lacto-N-neotetraose epitope e.g. it may be a 1st and/or 1gtB knockout strain [6]. LOS may lack at least one wild-type primary O-linked fatty acid [33]. LOS having. The LOS may have no .alpha. chain. The LOS may comprise GlcNAc-Hep.sub.2phosphoethanolamine-KDO.sub.2-Lipid A [34].
[0028] The vesicles may include one, more than one, or (preferably) zero PorA serosubtypes. Modification of meningococcus to provide multi-PorA OMVs is known e.g. from references 1 and 35. Conversely, modification to remove PorA is also known e.g. from reference 6.
[0029] The vesicles may be free from one of both of PorA and FrpB. Preferred vesicles are PorA-free.
[0030] The invention may be used with mixtures of vesicles from different strains. For instance, reference 36 discloses vaccine comprising multivalent meningococcal vesicle compositions, comprising a first vesicle derived from a meningococcal strain with a serosubtype prevalent in a country of use, and a second vesicle derived from a strain that need not have a serosubtype prevent in a country of use. Reference 37 also discloses useful combinations of different vesicles. A combination of vesicles from strains in each of the L2 and L3 immunotypes may be used in some embodiments.
Bacteria
[0031] As mentioned above, OMVs of the invention are prepared from meningococci which over-express the relevant antigen(s) due to genetic modification. The invention also provides these bacteria. The bacteria can be used for preparing OMVs of the invention.
[0032] In addition to genetic modification(s) which cause over-expression of the antigen(s) of interest, the bacteria may include one or more further modifications. For instance, the bacterium may have a knockout of one or more of lpxL1, 1gtB, porA, frpB, synX, 1gtA, mltA and/or lst.
[0033] The bacterium, may have low endotoxin levels, achieved by knockout of enzymes involved in LPS biosynthesis [38, 39].
[0034] The bacterium may be from any serogroup e.g. A, B, C, W135, Y. It is preferably serogronp B.
[0035] The bacterium may be of any serotype (e.g., 1, 2a, 2b, 4, 14, 15, 16, etc.), any serosubtype, and any immunotype (e.g. L1; L2; L3; L3,3,7; L10; etc.). Vesicles can usefully be prepared from strains having one of the following subtypes: P1.2; P1.2,5; P1.4; P1.5; P1.5,2; P1.5,c; P1.5c,10; P1.7,16; P1.7,16b; P1.7h,4; P1.9; P1.15; P1.9,15; P1.12,13; P1.13; P1.14; P1.21,16; P1.22,14.
[0036] The bacterium may be from any suitable lineage, including hyperinvasive and hypervirulent lineages e.g. any of the following seven hypervirulent lineages: subgroup I; subgroup III; subgroup IV-1; ET-5 complex; ET-37 complex; A4 cluster; lineage 3. These lineages have been defined by multilocus enzyme electrophoresis (MLEE), but multilocus sequence typing (MLST) has also been used to classify meningococci [ref. 40] e.g. the ET-37 complex is the ST-11 complex by MLST, the ET-5 complex is ST-32 (ET-5), lineage 3 is ST-41/44, etc.
[0037] In some embodiments a bacterium may include one or more of the knockout and/or hyper-expression mutations disclosed in references 16 and 41-43. Suitable genes for modification include: (a) Cps, CtrA, CtrB, CtrC, CtrD, FrpB, GalE, HtrB/MsbB, LbpA, LbpB, LpxK, Opa, Opc, PilC, PorB, SiaA, SiaB, SiaC, SiaD, TbpA, and/or TbpB [41]; (b) CtrA, CtrB, CtrC, CtrD, FrpB, GalE, HtrB/MsbB, LbpA, LbpB, LpxK, Opa, Opc, PhoP, PilC, PmrE, PmrF, SiaA, SiaB, SiaC, SiaD, TbpA, and/or TbpB; (c) ExbB, ExbD, rmpM, CtrA, CtrB, CtrD, GalE, LbpA, LpbB, Opa, Opc, PilC, PorB, SiaA, SiaB, SiaC, SiaD, TbpA, and/or TbpB; and (d) CtrA, CtrB, CtrD, FrpB, OpA, OpC, PilC, P or B, SiaD, SynA, SynB, and/or SynC.
[0038] A bacterium may have one or more, or all, of the following characteristics: (i) down-regulated or knocked-out LgtB and/or GalE to truncate the meningococcal LOS; (ii) up-regulated TbpA; (iii) up-regulated NhhA; (iv) up-regulated Omp85; (v) up-regulated LbpA; (vi) up-regulated NspA; (vii) knocked-out PorA; (viii) down-regulated or knocked-out FrpB; (ix) down-regulated or knocked-out Opa; (x) down-regulated or knocked-out Opc; (xii) deleted cps gene complex. A truncated LOS can be one that does not include a sialyl-lacto-N-neotetraose epitope e.g. it might be a galactose-deficient LOS. The LOS may have no .alpha. chain.
Strain Production
[0039] The invention provides a process for preparing a meningococcal strain suitable for OMV preparation, comprising steps of (i) choosing a starting strain which expresses a first amount of an antigen when grown in specific culture conditions, then (ii) modifying the starting strain to provide a modified strain, wherein the modified strain expresses a second amount of the antigen when grown in the same specific culture conditions, wherein the second amount is higher than the first amount; wherein the antigen is either NHBA or NadA. The second amount of NHBA or NadA is usefully at least 10%, higher than the first amount, measured in mass of the relevant antigen per unit mass of bacteria, and is more usefully at least 20%, 30%, 40%, 50%, 75%, 100% or more.
[0040] The invention provides a process for preparing a meningococcal strain suitable for OMV preparation, comprising steps of (i) choosing a starting strain which expresses NHBA and/or NadA; and (ii) modifying the starting strain to increase the amount of NHBA and/or NadA which it expresses. The increased amount after modification in step (ii) is usefully at least 10%, higher than the first amount, measured in mass of the relevant antigen per unit mass of bacteria, and is more usefully at least 20%, 30%, 40%, 50%, 75%, 100% or more.
[0041] Either of these processes can be followed by a step of (iii) culturing the modified bacteria obtained in step (ii) to provide a bacterial culture.
[0042] In step (ii), the modification to increase expression of NHBA and/or NadA can be any of the modifications discussed above. For instance, the strain can be modified by knocking out expression of NadR, thereby increasing expression of NadA. The strain can also be modified to increase or decrease expression of other polypeptides, as described elsewhere herein e.g. to increase its fHbp expression, such as by introducing a gene which encodes a constitutively-active mutant FNR.
[0043] The invention also provides a process for preparing a meningococcal vesicle, comprising a step of treating a bacterial culture obtained by a process of the invention (as described above) such that its outer membrane forms vesicles. This treatment step can use any of the techniques discussed above.
[0044] The invention also provides a process for preparing a meningococcal vesicle, comprising a step of treating a meningococcus of the invention such that its outer membrane forms vesicles. This treatment step can use any of the techniques discussed above.
[0045] Useful starting strains are in meningococcus serogroup B. Four useful starting meningococcal strains for preparing bacteria which over-express an antigen of interest are MC58, NZ05/33, H44/76 and GB013. MC58 has PorA serosubtype 1.7,16; NZ05/33 has serosubtype 1.7-2.4; H44/76 has serosubtype 1.7,16; and GB013 has serosubtype 1.22,9.
Isogenic Panels
[0046] A third aspect of the invention provides a panel of bacterial strains (e.g. meningococci), each member of which is isogenic except for a single gene which in each strain encodes a different variant of an antigen of interest. Thus the only genetic difference between each member of the panel is the coding sequence for this antigen. This panel can be used to study the immunological effect of polymorphic forms of a gene of interest found in different wild-type strains, without having to worry about variability due to differences in those strains which are unrelated to the antigen of interest. For instance, these panels can be used as test strains in a serum bactericidal antibody assay to provide a constant genetic background for assessing the cross-population killing of bacteria by antibodies which were raised against a specific sequence variant.
[0047] A useful panel for an antigen of interest can be made be selecting a starting strain of meningococcus. A useful starting strain does not express the antigen of interest; if the starting strain does express the antigen of interest then expression of the endogenous gene can be knocked out e.g. by insertion of a marker gene. To create a panel, a site in the bacterial genome is chosen for insertion of a gene encoding the antigen of interest. This site can be under the control of a promoter, such that different coding sequences can be introduced for expression from this promoter, or it can lack a promoter, in which case the introduced sequences should include a promoter. An important feature of the panel is that each member has the same promoter for expression of the antigen of interest, in the same location in the genome, such that the only genetic difference between them is the coding sequence for the antigen of interest.
[0048] The antigen of interest, which differs between panel members, can be any useful antigen which exists in polymorphic forms across a bacterial population. Thus, for meningococcus, the antigen of interest could be e.g. fHbp, NadA, NHBA, Omp85, HmbR, NhhA, App, NspA, TbpA, etc.
[0049] The general approach of creating an isogenic panel for testing the effect of sequence variability is not restricted to meningococcus and can be used for any other bacterium.
Antigens
NHBA (Neisserial Heparin Binding Antigen)
[0050] NHBA [11] was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] gene NMB2132 (GenBank accession number GI:7227388; SEQ ID NO: 9 herein). Sequences of NHBA from many strains have been published since then. For example, allelic forms of NHBA (referred to as protein `287`) can be seen in FIGS. 5 and 15 of reference 44, and in example 13 and FIG. 21 of reference 45 (SEQ IDs 3179 to 3184 therein). Various immunogenic fragments of NHBA have also been reported.
[0051] Preferred NHBA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 9; and or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 9, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 9.
[0052] The most useful NHBA antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 9. Advantageous NHBA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
[0053] NadA (Neisserial adhesin A)
[0054] The NadA antigen was included in the published genome sequence for meningococcal serogroup B strain MC 58 [68] as gene NMB1994 (GenBank accession numbers GI:7227256; SEQ ID NO: 10 herein). The sequences of NadA antigen from many strains have been published since then, and the protein's activity as a Neisserial adhesin has been well documented. Various immunogenic fragments of NadA have also been reported.
[0055] Preferred NadA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 10; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 10, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 10.
[0056] The most useful NadA antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 10. Advantageous NadA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject. SEQ ID NO: 6 is one such fragment.
HmbR
[0057] The full-length HmbR sequence was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB1668 (SEQ ID NO: 7 herein). Reference 46 reports a HmbR sequence from a different strain (SEQ ID NO: 8 herein), and reference 15 reports a further sequence (SEQ ID NO: 19 herein). SEQ ID NOs: 7 and 8 differ in length by 1 amino acid and have 94.2% identity. SEQ ID NO: 19 is one amino acid shorter than SEQ ID NO: 7 and they have 99% identity (one insertion, seven differences) by CLUSTALW. The invention can use any such HmbR polypeptide.
[0058] The invention can use a polypeptide that comprises a full-length HmbR sequence, but it will often use a polypeptide that comprises a partial HmbR sequence. Thus in some embodiments a HmbR sequence used according to the invention may comprise an amino acid sequence having at least i % sequence identity to SEQ ID NO: 7, where the value of i is 50, 60, 70, 80, 90, 95, 99 or more. In other embodiments a HmbR sequence used according to the invention may comprise a fragment of at least j consecutive amino acids from SEQ ID NO: 7, where the value of j is 7, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more. In other embodiments a HmbR sequence used according to the invention may comprise an amino acid sequence (i) having at least i % sequence identity to SEQ ID NO: 7 and/or (ii) comprising a fragment of at least j consecutive amino acids from SEQ ID NO: 7.
[0059] Preferred fragments of j amino acids comprise an epitope from SEQ ID NO: 7. Such epitopes will usually comprise amino acids that are located on the surface of HmbR. Useful epitopes include those with amino acids involved in HmbR's binding to haemoglobin, as antibodies that bind to these epitopes can block the ability of a bacterium to bind to host haemoglobin. The topology of HmbR, and its critical functional residues, were investigated in reference 47. Fragments that retain a transmembrane sequence are useful, because they can be displayed on the bacterial surface e.g. in vesicles. Examples of long fragments of HmbR correspond to SEQ ID NOs: 21 and 22. If soluble HmbR is used, however, sequences omitting the transmembrane sequence, but typically retaining epitope(s) from the extracellular portion, can be used.
[0060] The most useful HmbR antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 7. Advantageous HmbR antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
[0061] fHbp (factor H binding protein)
[0062] The fHbp antigen has been characterised in detail. It has also been known as protein `741` [SEQ IDs 2535 & 2536 in ref 45], `NMB1870`, `GNA1870` [refs. 48-50], `P2086`, `LP2086` or `ORF2086` [51-53]. It is naturally a lipoprotein and is expressed across all meningococcal serogronps. The structure of fHbp's C-terminal immunodominant domain (`fHbpC`) has been determined by NMR [54]. This part of the protein forms an eight-stranded .beta.-barrel, whose strands are connected by loops of variable lengths. The barrel is preceded by a short .alpha.-helix and by a flexible N-terminal tail.
[0063] The fHbp antigen falls into three distinct variants [55] and it has been found that serum raised against a given family is bactericidal within the same family, but is not active against strains which express one of the other two families i.e. there is intra-family cross-protection, but not inter-family cross-protection. The invention can use a single fHbp variant, but is will usefully include a fHbp from two or three of the variants. Thus it may use a combination of two or three different fHbps, selected from: (a) a first protein, comprising an amino acid sequence having at least a% sequence identity to SEQ ID NO: 1 and/or comprising an amino acid sequence consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 1; (b) a second protein, comprising an amino acid sequence having at least b% sequence identity to SEQ ID NO: 2 and/or comprising an amino acid sequence consisting of a fragment of at least y contiguous amino acids from SEQ ID NO: 2; and/or (c) a third protein, comprising an amino acid sequence having at least c% sequence identity to SEQ ID NO: 3 and/or comprising an amino acid sequence consisting of a fragment of at least z contiguous amino acids from SEQ ID NO: 3.
[0064] The value of a is at least 85 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or more. The value of b is at least 85 e.g. 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or more. The value of c is at least 85 e.g. 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or more. The values of a, b and c are not intrinsically related to each other.
[0065] The value of x is at least 7 e.g. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250). The value of y is at least 7 e.g. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250). The value of z is at least 7 e.g. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250). The values of x, y and z are not intrinsically related to each other.
[0066] Where the invention uses a single fHbp variant, a composition may include a polypeptide comprising (a) an amino acid sequence having at least a% sequence identity to SEQ ID NO: 1 and/or comprising an amino acid sequence consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 1; or (b) an amino acid sequence having at least b% sequence identity to SEQ ID NO: 2 and/or comprising an amino acid sequence consisting of a fragment of at least y contiguous amino acids from SEQ ID NO: 2; or (c) an amino acid sequence having at least c% sequence identity to SEQ ID NO: 3 and/or comprising an amino acid sequence consisting of a fragment of at least z contiguous amino acids from SEQ ID NO: 3.
[0067] Where the invention uses a fHbp from two or three of the variants, a composition may include a combination of two or three different fHbps selected from: (a) a first polypeptide, comprising an amino acid sequence having at least a% sequence identity to SEQ ID NO: 1 and/or comprising an amine acid sequence consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 1; (b) a second polypeptide, comprising an amino acid sequence having at least b% sequence identity to SEQ ID NO: 2 and/or comprising an amino acid sequence consisting of a fragment of at least y contiguous amino acids from SEQ ID NO: 2; and/or (c) a third polypeptide, comprising an amino acid sequence having at least c% sequence identity to SEQ ID NO: 3 and/or comprising an amino acid sequence consisting of a fragment of at least z contiguous amino acids from SEQ ID NO: 3. The first, second and third polypeptides have different amino acid sequences.
[0068] Where the invention uses a fHbp from two of the variants, a composition can include both: (a) a first polypeptide, comprising an amino acid sequence having at least a% sequence identity to SEQ ID NO: 1 and/or comprising an amino acid sequence consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 1; and (b) a second polypeptide, comprising an amino acid sequence having at least b% sequence identity to SEQ ID NO: 2 and/or comprising an amino acid sequence consisting of a fragment of at least y contiguous amino acids from SEQ ID NO: 2. The first and second polypeptides have different amino acid sequences.
[0069] Where the invention uses a fHbp from two of the variants, a composition can include both: (a) a first polypeptide, comprising an amino acid sequence having at least a% sequence identity to SEQ ID NO: 1 and/or comprising an amino acid sequence consisting of a fragment of at least x contiguous amino acids from SEQ ID NO: 1; (b) a second polypeptide, comprising an amino acid sequence having at least c% sequence identity to SEQ ID NO: 3 and/or comprising an. amino acid sequence consisting of a fragment of at least z contiguous amino acids from SEQ ID NO: 3. The first and second polypeptides have different amino acid sequences.
[0070] Another useful fHbp which can be used according to the invention is one of the modified forms disclosed, for example, in reference 56 e.g. comprising SEQ ID NO: 20 or 23 therefrom. These modified forms can elicit antibody responses which are broadly bactericidal against meningococci.
[0071] fHbp protein(s) in a OMV will usually be lipidated e.g. at a N-terminus cysteine. In other embodiments they will not be lipidated.
NspA (Neisserial surface protein A)
[0072] The NspA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB0663 (GenBank accession number GI:7225888; SEQ ID NO: 11 herein). The antigen was previously known from references 57 & 58. The sequences of NspA antigen from many strains have been published since then. Various immunogenic fragments of NspA have also been reported.
[0073] Preferred NspA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 11; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 11, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 11.
[0074] The most useful NspA antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 11. Advantageous NspA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
NhhA (Neisseria hia homologue)
[0075] The NhhA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB0992 (GenBank accession number GI:7226232; SEQ ID NO: 12 herein). The sequences of NhhA antigen from many strains have been published since e.g. refs 44 & 59, and various immunogenic fragments of NhhA have been reported. It is also known as Hsf.
[0076] Preferred NhhA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 12; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 12, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 12.
[0077] The most useful NhhA antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 12. Advantageous NhhA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
App (Adhesion and penetration protein)
[0078] The App antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB1985 (GenBank accession number GI:7227246; SEQ ID NO: 13 herein). The sequences of App antigen from many strains have been published since then. It has also been known as `ORF1` and `Hap`. Various immunogenic fragments of App have also been reported.
[0079] Preferred App antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 13; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 13, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 13.
[0080] The most useful App antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 13. Advantageous App antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
Omp85 (85 kDa outer membrane protein)
[0081] The Omp85 antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB0182 (GenBank accession number GI:7225401; SEQ ID NO: 14 herein). The sequences of Omp85 antigen from many strains have been published since then. Further information on Omp85 can be found in references 60 and 61. Various immunogenic fragments of Omp85 have also been reported.
[0082] Preferred Omp85 antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 14; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 14, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 14.
[0083] The most useful Omp85 antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 14. Advantageous Omp85 antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
TbpA
[0084] The TbpA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB0461 (GenBank accession number GI:7225687; SEQ ID NO: 23 herein). The sequences of TbpA from many strains have been published since then. Various immunogenic fragments of TbpA have also been reported.
[0085] Preferred TbpA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 23; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 23, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 23.
[0086] The most useful TbpA antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 23. Advantageous TbpA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
TbpB
[0087] The TbpB antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB1398 (GenBank accession number GI:7225686; SEQ ID NO: 24 herein). The sequences of TbpB from many strains have been published since then. Various immunogenic fragments of TbpB have also been reported.
[0088] Preferred TbpB antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 24; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 24, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 24.
[0089] The most useful TbpB antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 24. Advantageous TbpB antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
Cu,Zn-superoxide Dismutase
[0090] The Cu,Zn-superoxide dismutase antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [68] as gene NMB1398 (GenBank accession number GI:7226637; SEQ ID NO: 25 herein). The sequences of Cu,Zn-superoxide dismutase from many strains have been published since then. Various immunogenic fragments of Cu,Zn-superoxide dismutase have also been reported.
[0091] Preferred Cu,Zn-superoxide dismutase antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 25; and/or (b) comprising a fragment of at least `n` consecutive amino acids of SEQ ID NO: 25, wherein `n` is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 25.
[0092] The most useful Cu,Zn-superoxide dismutase antigens can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 25. Advantageous Cu,Zn-superoxide dismutase antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject.
Pharmaceutical Compositions
[0093] Vesicles of the invention are useful as active ingredients in immunogenic pharmaceutical compositions for administration to a patient. These will typically include a pharmaceutically acceptable carrier, and a thorough discussion of such carriers is available in reference 62.
[0094] Effective dosage volumes can be routinely established, but a typical human dose of the composition has a volume of about 0.5 ml e.g. for intramuscular injection. The RIVM OMV-based vaccine was administered in a 0.5 ml volume [63] by intramuscular injection to the thigh or upper arm. MeNZB.TM. is administered in a 0.5 ml by intramuscular injection to the anterolateral thigh or the deltoid region of the arm. Similar doses may be used for other delivery routes e.g, an intranasal OMV-based vaccine for atomisation may have a volume of about 100 .mu.l or about 130 .mu.l per spray, with four sprays administered to give a total dose of about 0.5 ml.
[0095] The pH of a composition of the invention is usually between 6 and 8, and more preferably between 6.5 and 7.5 (e.g. about 7). The pH of the RIVM OMV-based vaccine is 7.4 [64], and a pH<7.5 is preferred for compositions of the invention. The RIVM OMV-based vaccine maintains pH by using a 10 mM Tris/HCl buffer, and stable pH in compositions of the invention may be maintained by the use of a buffer e.g. a Tris buffer, a citrate buffer, phosphate buffer, or a histidine buffer. Thus compositions of the invention will generally include a buffer.
[0096] The composition may be sterile and/or pyrogen-free. Compositions of the invention may be isotonic with respect to humans.
[0097] Compositions of the invention for administration to patients are immunogenic, and are more preferably vaccine compositions. Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic. Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, as needed. By `immunologically effective amount`, it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. The antigen content of compositions of the invention will generally be expressed in terms of the amount of protein per dose. A dose of about 0.9 mg protein per ml is typical for OMV-based intranasal vaccines.
[0098] Compositions of the invention may include an immunological adjuvant. Thus, for example, they may include an aluminium salt adjuvant or an oil-in-water emulsion (e.g. a squalene-in-water emulsion). Suitable aluminium salts include hydroxides (e.g. oxyhydroxides), phosphates (e.g. hydroxyphosphates, orthophosphates), (e.g. see chapters 8 & 9 of ref. 65), or mixtures thereof. The salts can take any suitable form (e.g. gel, crystalline, amorphous, etc.), with adsorption of antigen to the salt being preferred. The concentration of Al.sup.+++ in a composition for administration to a patient is preferably less than 5 mg/ml e.g. .ltoreq.4 mg/ml, .ltoreq.3 mg/ml, .ltoreq.2 mg/ml, .ltoreq.1 mg/ml, etc. A preferred range is between 0.3 and 1 mg/ml. A maximum of 0.85 mg/dose is preferred. Aluminium hydroxide adjuvants are particularly suitable for use with meningococcal vaccines.
[0099] Meningococci affect various areas of the body and so the compositions of the invention may be prepared in various liquid forms. For example, the compositions may be prepared as injectable, either as solutions or suspensions. The composition may be prepared for pulmonary administration e.g, by an inhaler, using a fine spray. The composition may be prepared for nasal, aural or ocular administration e.g. as spray or drops. Injectables for intramuscular administration are typical.
[0100] Compositions of the invention may include an antimicrobial, particularly when packaged in multiple dose format. Antimicrobials such as thiomersal and 2-phenoxyethanol are commonly found in vaccines, but it is preferred to use either a mercury-free preservative or no preservative at all.
[0101] Compositions of the invention may comprise detergent e.g. a Tween (polysorbate), such as Tween 80. Detergents are generally present at low levels e.g. <0.01%.
[0102] Compositions of the invention may include residual detergent (e.g. deoxycholate) from OMV preparation. The amount of residual detergent is preferably less than 0.4 .mu.g (more preferably less than 0.2 .mu.g) for every .mu.g of MenB protein.
[0103] If a composition of the invention includes LOS, the amount of LOS is preferably less than 0.12 .mu.g (more preferably less than 0.05 .mu.g) for every .mu.g of protein.
[0104] Compositions of the invention may include sodium salts (e.g. sodium chloride) to give tonicity. A concentration of 10.+-.2 mg/ml NaCl is typical e.g. about 9 mg/ml.
[0105] Methods of Treatment
[0106] The invention also provides a method for raising an immune response in a mammal, comprising administering a composition of the invention to the mammal. The immune response is preferably protective and preferably involves antibodies. The method may raise a booster response in a patient that has already been primed against N. meningitidis.
[0107] The mammal is preferably a human. Where the vaccine is for prophylactic use, the human is preferably a child (e.g. a toddler or infant) or a teenager; where the vaccine is for therapeutic use, the human is preferably an adult. A vaccine intended for children may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc.
[0108] The invention also provides vesicles of the invention for use as a medicament. The medicament is preferably used to raise an immune response in a mammal (i.e. it is an immunogenic composition) and is more preferably a vaccine.
[0109] The invention also provides the use of vesicles of the invention in the manufacture of a medicament for raising an immune response in a mammal.
[0110] These uses and methods are preferably for the prevention and/or treatment of a disease caused by N. meningitidis e.g. bacterial (or, more specifically, meningococcal) meningitis, or septicemia.
[0111] One way of checking efficacy of therapeutic treatment involves monitoring Neisserial infection after administration of the composition of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses against antigens after administration of the composition. Immunogenicity of compositions of the invention can be determined by administering them to test subjects (e.g. children 12-16 months age, or animal models [66]) and then determining standard parameters including serum bactericidal antibodies (SBA) and ELISA titres (GMT). These immune responses will generally be determined around 4 weeks after administration of the composition, and compared to values determined before administration of the composition. A SBA increase of at least 4-fold or 8-fold is preferred. Where more than one dose of the composition is administered, more than one post-administration determination may be made.
[0112] In general, compositions of the invention are able to induce serum bactericidal antibody responses after being administered to a subject. These responses are conveniently measured in mice and are a standard indicator of vaccine efficacy. Serum bactericidal activity (SBA) measures bacterial killing mediated by complement, and can be assayed using human or baby rabbit complement. WHO standards require a vaccine to induce at least a 4-fold rise in SBA in more than 90% of recipients. MeNZB.TM. elicits a 4-fold rise in SBA 4-6 weeks after administration of the third dose.
[0113] Preferred compositions can confer an antibody titre in a human subject patient that is superior to the criterion for seroprotection for an acceptable percentage of subjects. Antigens with an associated antibody titre above which a host is considered to be seroconverted against the antigen are well known, and such titres are published by organisations such as WHO. Preferably more than 80% of a statistically significant sample of subjects is seroconverted, more preferably more than 90%, still more preferably more than 93% and most preferably 96-100%.
[0114] Compositions of the invention will generally be administered directly to a patient. Direct delivery may be accomplished by parenteral injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by any other suitable route. The invention may be used to elicit systemic and/or mucosal immunity. Intramuscular administration to the thigh or the upper arm is preferred. Injection may be via a needle (e.g. a hypodermic needle), but needle-free injection may alternatively be used. A typical intramuscular dose is 0.5 ml.
[0115] Dosage treatment can be a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. A primary dose schedule may be followed by a booster dose schedule. Suitable timing between priming doses (e.g. between 4-16 weeks), and between priming and boosting, can be routinely determined. The OMV-based RIVM vaccine was tested using a 3- or 4-dose primary schedule, with vaccination at 0, 2 & 8 or 0, 1, 2 & 8 months. MeNZB.TM. is administered as three doses at six week intervals.
[0116] Compositions of the invention may be used to induce bactericidal antibody responses against more than one hypervirulent lineage of meningococcus. In particular, they can preferably induce bactericidal responses against two or three of the following three hypervirulent lineages: (i) cluster A4; (ii) ET5 complex; and (iii) lineage 3. They may additionally induce bactericidal antibody responses against one or more of hypervirulent lineages subgroup I, subgroup III, subgroup IV-1 or ET-37 complex, and against other lineages e.g. hyperinvasive lineages. This does not necessarily mean that the composition can induce bactericidal antibodies against each and every strain of meningococcus within these hypervirulent lineages e.g. rather, for any given group of four of more strains of meningococcus within a particular hypervirulent lineage, the antibodies induced by the composition are bactericidal against at least 50% (e.g. 60%, 70%, 80%, 90% or more) of the group. Preferred groups of strains will include strains isolated in at least four of the following countries: GB, AU, CA, NO, IT, US, NZ, NL, BR, and CU. The serum preferably has a bactericidal titre of at least 1024 (e.g. 2.sup.10, 2.sup.11, 2.sup.12, 2.sup.13, 2.sup.14, 2.sup.15, 2.sup.16, 2.sup.17, 2.sup.18 or higher, preferably at least 2.sup.14) e.g. the serum is able to kill at least 50% of test bacteria of a particular strain when diluted 1/1024.
[0117] Useful compositions can induce bactericidal responses against the following strains of serogroup B meningococcus: (i) from cluster A4, strain 961-5945 (B:2b:P1.21,16) and/or strain G2136 (B:-); (ii) from ET-5 complex, strain MC58 (B:15:P1.7,16b) and/or strain 44/76 (B:15:P1.7,16); (iii) from lineage 3, strain 394/98 (B:4;P1.4) and/or strain BZ198 (B:NT:-). More preferred compositions can induce bactericidal responses against strains 961-5945, 44/76 and 394/98.
[0118] Strains 961-5945 and G2136 are both Neisseria MLST reference strains [ids 638 & 1002 in ref. 67]. Strain MC58 is widely available (e.g. ATCC BAA-335) and was the strain sequenced in reference 68. Strain 44/76 has been widely used and characterised (e.g. ref 69) and is one of the Neisseria MLST reference strains [id 237 in ref. 67; row 32 of Table 2 in ref 40]. Strain 394/98 was originally isolated in New Zealand in 1998, and there have been several published studies using this strain, (e.g. refs. 70 & 71). Strain BZ198 is another MLST reference strain (id 409 in ref 67; row 41 of Table 2 in ref. 40).
Further Antigenic Components
[0119] In addition to vesicles of the invention, an immunogenic composition can include further antigens.
[0120] In some embodiments, a composition includes one or more capsular saccharides from meningococci e.g. from serogroups A, C, W135 and/or Y. These saccharides will usually be conjugated to a protein carrier. A composition of the invention may include one or more conjugates of capsular saccharides from 1, 2, 3, or 4 of meningococcal serogroup A, C, W135 and Y e.g. A+C, A+W135, A+Y, C+W135, C+Y, W135+Y, A+C+W135, A+C+Y, A+W135+Y, A+C+W135+Y, etc. Components including saccharides from all four of serogroups A, C, W135 and Y are ideal.
[0121] As well as containing antigens from N. meningitidis, compositions may include antigens from further pathogens. For example, the composition may comprise one or more of the following further antigens:
[0122] an antigen from Streptococcus pneumoniae, such as a saccharide (typically conjugated)
[0123] an antigen from hepatitis B virus, such as the surface antigen HBsAg.
[0124] an antigen from Bordetella pertussis, such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from B. pertussis, optionally also in combination with pertactin and/or agglutinogens 2 and 3.
[0125] a diphtheria antigen, such as a diphtheria toxoid.
[0126] a tetanus antigen, such as a tetanus toxoid.
[0127] a saccharide antigen from Haemophilus influenzae B (Hib), typically conjugated.
[0128] inactivated poliovirus antigens.
[0129] Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens. DTP combinations are thus preferred.
[0130] If a Hib saccharide is included (typically as a conjugate), the saccharide moiety may be a polysaccharide (e.g. full-length polyribosylribitol phosphate (PRP) as purified from bacteria), but it is also possible to fragment the purified saccharide to make oligosaccharides (e.g: MW from .about.1 to .about.5 kDa) e.g. by hydrolysis. The concentration of Hib conjugate in a composition will usually be in the range of 0.5 .mu.g to 50 .mu.g e.g. from 1-20 .mu.g, from 10-15 .mu.g, from 12-16 .mu.g, etc. The amount may be about 15 g, or about 12.5 .mu.g in some embodiments. A mass of less than 5 .mu.g may be suitable [72] e.g. in the range 1-5 .mu.g, 2-4 .mu.g, or about 2.5 .mu.g. As described above, in combinations that include Hib saccharide and meningococcal saccharides, the dose of the former may be selected based on the dose of the latter (in particular, with multiple meningococcal serogroups, their mean mass). Further characteristics of Hib conjugates are as disclosed above for meningococcal conjugates, including choice of carrier protein (e.g. CRM197 or tetanus toxoid), linkages, ratios, etc.
[0131] If a S. pneumoniae antigen is included, this may be a polypeptide or a saccharide. Conjugates capsular saccharides are particularly useful for immunising against pneumococcal. The saccharide may be a polysaccharide having the size that arises during purification of the saccharide from bacteria, or it may be an oligosaccharide achieved by fragmentation of such a polysaccharide. In the 7-valent PREVNAR.TM. product, for instance, 6 of the saccharides are presented as intact polysaccharides while one (the 18C serotype) is presented as an oligosaccharide. A composition may include a capsular saccharide from one or more of the following pneumococcal serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and/or 33F. A composition may include multiple serotypes e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or more serotypes, 7-valent, 9-valent, 10-valent, 11-valent and 13-valent conjugate combinations are already known in the art, as is a 23-valent unconjugated combination. For example, an 10-valent combination may include saccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. An 11-valent combination may further include saccharide from serotype 3. A 12-valent combination may add to the 10-valent mixture: serotypes 6A and 19A; 6A and 22F; 19A and 22F; 6A and 15B; 19A and 15B; r 22F and 15B; A 13-valent combination may add to the 11-valent mixture: serotypes 19A and 22F; 8 and 12F; 8 and 15B; 8 and 19A; 8 and 22F; 12F and 15B; 12F and 19A; 12F and 22F; 15B and 19A; 15B and 22F. etc. Further characteristics of pneumococcal conjugates are as disclosed above for meningococcal conjugates, including choice of carrier protein (e.g. CRM197 or tetanus toxoid), linkages, ratios, etc. Where a composition includes more than one conjugate, each conjugate may use the same carrier protein or a different carrier protein. Reference 73 describes potential advantages when using different carrier proteins in multivalent pneumococcal conjugate vaccines.
General
[0132] The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., references 74-80, etc.
[0133] The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g; X+Y.
[0134] The term "about" in relation to a numerical value x is optional and means, for example, x.+-.10%.
[0135] Where the invention concerns an "epitope", this epitope may be a B-cell epitope and/or a T-cell epitope, but will usually be a B-cell epitope. Such epitopes can be identified empirically (e.g. using PEPSCAN [81, 82] or similar methods), or they can be predicted (e.g. using the Jameson-Wolf antigenic index [83], matrix-based approaches [84], MAPITOPE [85], TEPITOPE [86, 87], neural networks [88], OptiMer & EpiMer [89, 90], ADEPT [91], Tsites [92], hydrophilicity [93], antigenic index [94] or the methods disclosed in references 95-99, etc.). Epitopes are the parts of an antigen that are recognised by and bind to the antigen binding sites of antibodies or T-cell receptors, and they may also be referred to as "antigenic determinants".
[0136] References to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. 100. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is disclosed in ref. 101.
[0137] The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
BRIEF DESCRIPTION OF DRAWINGS
[0138] FIG. 1 illustrates the approach for constructing an isogenic panel by knocking out nadA and nhba (GNA2132) to create a background strain.
[0139] FIG. 2 shows the insertion of fHbp genes into the background strain to make a panel of isogenic strains expressing different fHbp genes under the control of a Ptac promoter.
[0140] FIG. 3A-FIG. 3B shows expression levels of fHbp in the isogenic panel strains described in FIG. 2.
[0141] FIG. 4A-FIG. 4B shows expression of NadA (upper panel) and NadR (lower panel) in eight wild-type strains (FIG. 4A) or their NadR knockout forms (FIG. 4B). The numbers in FIG. 4A show the number of TAAA tetranucleotide repeats in the strain. FIG. 4C-FIG. 4D shows expression of NadA and NadR in 7 strains, in the presence of absence of 4HPA.
[0142] FIG. 5A-FIG. 5C shows (FIG. 5A) starting strain MC58 (FIG. 5B) MC58.DELTA.nhba and (FIG. 5C) MC58.DELTA.nhba transformed with a complementing nhba gene with an upstream CREN and IPTG-inducible promoter.
[0143] FIG. 6 shows NHBA expression by MC58 and derivative strains. The left two lanes show expression in MC58 and MC58.DELTA.nhba. The next 8 lanes show expression in complemented strains at four concentrations of IPTG. The lanes are arranged in pairs, with the right-hand lane being a strain complemented with nhba having an upstream CREN.
[0144] FIG. 7 shows NHBA expression by 95N477 and derivative strains. The left two lanes show expression in 95N477 and 95N477.DELTA.nhba. The next 5 lanes show expression in complemented strains at the indicated concentrations of IPTG.
[0145] FIG. 8 shows NHBA expression for five strains in an isogenic panel. From top to bottom the expressed NHBA is from strain NZ98/254, UK013, UK355, 2996 and NM117.
MODES FOR CARRYING OUT THE INVENTION
NHBA
[0146] The endogenous nhba gene is knocked out in various serogroup B strains to create strains MC58.DELTA.nhba, 95N477.DELTA.nhba, NGH38.DELTA.nhba and UK013.DELTA.nhba. These strains are then transformed with pCOMPpind-287 vector containing a gene encoding nhba from strain 394/98, with or without an upstream CREN (contact regulatory element of Neisseria), under the control of an IPTG-inducible promoter. The vectors insert the nhba gene (.+-.CREN) between the endogenous nmb1428 and nmb1429 genes by homologous recombination.
[0147] FIG. 5 shows the starting MC58 strain, the MC58.DELTA.nhba strain, and the complemented MC58 strain (+CREN). FIG. 6 shows expression of NHBA by the various MC58 strains with increasing IPTG concentration. The complemented strains show high levels of inducible NHBA expression, with the highest levels seen with the inserted gene has an upstream CREN.
[0148] FIG. 7 shows expression in the 95N477 strains. The endogenous nhba gene in this strain encodes a 427aa protein, whereas the inserted complementing gene has 492aa. Increased expression levels of the larger NHBA protein are clearly visible, and this expression increases with IPTG concentration.
[0149] Although in some strains (e.g. M4407) it was not possible to obtain a .DELTA.nhba knockout using the transformation protocols, for strains which could be transformed these results show that strains which over-express NHBA can readily be obtained.
NadR (NMB1843)
[0150] The nadA gene is present in approximately 50% of meningococcal isolates. NadA exhibits growth-phase dependent expression, with maximal levels in the stationary growth phase of all strains tested. Expression is controlled by a tetranucleotide repeat (TAAA) located upstream of the nadA promoter. The number of repeats can be modified during replication through slipped strand mispairing, and consequently can influence the expression of the nadA gene by creating variants where changes in the repeat number result in promoters with low, medium or high activity.
[0151] An area of the nadA promoterm upstream of the TAAA repeat, is responsible for repression of nadA expression during logarithmic phase of growth. This area is called the `GPR region`. DNA-affinity fractionation identified a protein present in meningococcus crude extracts which binds to the GPR region. This protein is NadR (NMB1843) and is a member of the MarR family of repressors. NadR binds to three operators (binding sites) in the nadA promoter and results in repression of NadA expression. Knockout of NadR in strains expressing high, medium or low levels of NadA results in almost comparable high level expression in each strain. Thus NadR is the repressor that contributes to the differential expression levels exhibited by meningococcal strains, or phase variants in the same strain, with different numbers of repeats in their promoter. NadR is expressed to similar levels in different strains but can repress more or less efficiently the nadA promoter depending on the number of repeats present in the variant promoter.
[0152] Knockout of NadR in various meningococcus backgrounds results in almost comparable high levels of expression of NadA across the panel. Strains are transformed with the knockout construct for the allelic replacement of nmb1843 with a chloramphenicol cassette. Expression levels in eight different strains are shown in FIG. 4.
[0153] A small molecule ligand 4-hydroxyphenylacetic acid (4HPA) can induce NadA expression in vitro due to derepression of NadR (FIG. 4C). Addition of the molecule to the purified NadR protein in vitro can inhibit the binding activity of the protein for the nadA promoter. 4HPA is a metabolite of the catabolic pathway of the aromatic amino acids and is secreted in human saliva and urine, and so in vivo expression of NadA may be higher than is seen during in vitro growth.
[0154] Thus strains which over-express NadA can readily be obtained by inactivation of NadR and/or by addition of a small molecule inducer to the growth medium.
Isogenic Panel--NHBA
[0155] NHBA is an antigen in the 4CMenB product. An isogenic panel was used to study the potential cross protection of NHBA-induced bactericidal antibodies.
[0156] The nhba genes from six different meningococcal strains were amplified to provide the mature form of the polypeptide with a C-terminus histidine tag. These were cloned into the pET-21b+ plasmid vector and expressed in E. coli. The purified NHBA peptides were then used to immunize mice (20 .mu.g dose) and obtain mouse antisera. ELISA assays were performed in order to confirm the presence of antibodies in all the mouse sera obtained.
[0157] To evaluate the immunogenicity and the contribution of amino acid sequence variability to vaccine coverage, a starting strain was engineered to be susceptible to bactericidal killing only by anti-NHBA antibodies (rather than the other antigens in 4CMenB). N. meningitidis strain 5/99 naturally expresses high levels of NadA, but very low levels of NHBA and fHbp. Its nadA and nhba genes were respectively replaced by ery and kan resistance cassettes (5/99.DELTA..DELTA.). The nhba gene to be complemented was then inserted in the intergenic region between the open reading frames nmb1428 and nmb1429. Thus the final strain panel was isogenic except for the chosen nhba gene, and this gene should be inducable for expression at equal levels in all members of the panel.
[0158] FACS showed that the panel members showed a comparable amount of the different NHBA polypeptides in each strain (FIG. 8). Several mouse antisera raised against the different NHBA polypeptides were tested in western blot and the detection appeared to be variant-specific, showing a stronger recognition for the homologous variant.
[0159] The panel was also used for testing the bactericidal effect of the mouse antisera. As the strains were isogenic then any difference in bactericidal effect should arise only from the different expressed NHBA polypeptides. In parallel the sera were tested against wild-type strains which express the relevant NHBA polypeptide sequence, to see if the common genetic background of the isogenic panel did enable the detection of differences which would be concealed by natural variation if wild-type strains were used. Results were as follows:
TABLE-US-00001 Antiserum NHBA 5/99.DELTA..DELTA. Wild-type NZ98/254 >8192 8192 WC58 8192 512 UK013 256 128 UK355 128 256 2996 128 256 NM117 2048 4096
[0160] Thus the panel does seem to compensate for variability which is unrelated to the NHBA antigen itself. For instance, serum raised against the MC58 sequence is much more effective against the MC58 polypeptide in the isogenic panel than against the wild-type MC58 strain.
Isogenic Panel--fHbp
[0161] Sequencing of the fHbp gene in a large collection of meningococcal isolates revealed three variants with low levels of cross-protective bactericidal response. A serum bactericidal assay was used to evaluate the cross-protective capabilities of human antibodies raised against different fHbp variants, but the killing mediated by bactericidal antibodies in this assay is dependent by several factors. Thus the potential coverage of a single antigen may be difficult to estimate.
[0162] A genetic approach was used to overcome variability due to strain-specific serum susceptibility, limitations of compatible complement sources, and variable expression of fHbp and other surface-exposed factors affecting resistance to serum (e.g. the capsule). A well-characterized meningococcal isolate (5/99) was engineered to generate isogenic strains expressing ten different fHbp sub-variants from a constitutive heterologous promoter. The fHbp genes were inserted between endogenous nmb1428 and nmb1429 genes. This panel was then used as the test strain in a serum bactericidal antibody (SBA) assay to assess the ability of a single fHbp variant to elicit a broadly-protective immune response.
[0163] In order to have a genetic background to express different fHbp sub-variants without the interfering action of the other antigens, the nadA and nhba genes in the starting 5/99 strain were inactivated by insertion of erm and kan resistance cassettes, respectively (FIG. 1). The resulting double mutant strain (named 5/99.DELTA..DELTA.) was manipulated to express different fHbp subvariants under the control of a Ptac promoter to standardize the amount of fHbp expressed (FIGS. 1 & 2). In total, ten different fHbp coding sequences were cloned in the pComp-RBS vector and transferred to the 5/99.DELTA..DELTA. genetic background.
[0164] To evaluate the expression of fHbp in the recombinant strains, we performed FACS analysis using a mouse polyclonal serum against a single fHbp variant. The analysis showed a comparable amount of the different fHbp sub-variants on the surface of the recombinant strains generated (FIG. 3).
[0165] The recombinant strains were analyzed for their susceptibility to killing by bactericidal antibodies from mice in a SBA using rabbit complement. Pooled sera from mice immunized with the "universal vaccine" of reference 19 or with its GNA2091-fHbp component were tested for their ability to kill the 5/99 wild-type, the intermediate 5/99.DELTA..DELTA. strain expressing neither NHBA nor NadA antigens, and the ten recombinant strains. The 5/99 strain was killed by sera raised against the universal vaccine, but not by sera raised against the single antigen GNA2091-fHbp. The 5/99.DELTA..DELTA. strain was resistant to killing by all sera. All of the complemented strains except one showed significant susceptibility to sera derived from mice immunized with the universal vaccine or with GNA2091-fHbp antigen. The single surviving strain expressed a fHbp in family III, confirming the absence of cross-reactivity between the fHbp families. The nine susceptible strains confirm that the specific fHbp sequence in the universal vaccine can raise antibodies which are broadly protective across the whole of fHbp family 1.
[0166] The panel was also tested using sera obtained from human adults who were immunised with 4CMenB. The results were comparable to those seen using mice.
[0167] It will be understood that the invention is described above by way of example only and modifications may be made whilst remaining within the scope end spirit of the invention.
REFERENCES
[0168] [1] Claassen et al. (1996) Vaccine 14:1001-8.
[0169] [2] Koeberling et al. (2007) Vaccine 25:1912-20.
[0170] [3] Koeberling et al. (2008) J Infect Dis 198:262-70.
[0171] [4] Hou et al. (2005) J Infect Dis 192:580-90.
[0172] [5] WO2009/038889.
[0173] [6] Bonvehi et al. (2010) Clin Vacc Immunol 17:1460-6.
[0174] [7] Zollinger et al. (2010) Vaccine 28:5057-67.
[0175] [8] WO2004/015099.
[0176] [9] WO2006/081259.
[0177] [10] Deghmane et al. (2003) Infect Immun 71:2897-901.
[0178] [11] Serruto et al. (2010) PNAS USA 107:3770-5.
[0179] [12] Schielke et al. (2009) Mol Microbiol 72:1054-67.
[0180] [13] WO2004/014418.
[0181] [14] WO00/25811.
[0182] [15] WO2010/070453.
[0183] [16] WO02/09746.
[0184] [17] Oriente et al. (2010) J Bacteriol 192:691-701.
[0185] [18] U.S. provisional patent application 61/247,428.
[0186] [19] Giuliani et al. (2006) Proc Natl Acad Sci USA 103(29):10834-9.
[0187] [20] Donnelly et al. (2010) PNAS USA 107:19490-5.
[0188] [21] Kimura et al. (2010) Clin Vaccine Immunol. 2010 PMID: 21177912.
[0189] [22] WO02/09643.
[0190] [23] Katial et al. (2002) Infect. Immun. 70:702-707.
[0191] [24] U.S. Pat. No. 6,180,111.
[0192] [25] WO01/34642.
[0193] [26] WO2004/019977.
[0194] [27] European patent 0011243.
[0195] [28] Fredriksen et al. (1991) NIPH Ann. 14(2):67-80.
[0196] [29] WO01/91788.
[0197] [30] WO2005/004908.
[0198] [31] WO2006/046143.
[0199] [32] WO00/26384.
[0200] [33] U.S. Pat. No. 6,531,131
[0201] [34] U.S. Pat. No. 6,645,503
[0202] [35] de Kleijn et al. (2000) Vaccine 18:1456-66.
[0203] [36] WO03/105890.
[0204] [37] WO2006/024946
[0205] [38] WO99/10497.
[0206] [39] Steeghs et al. (2001) The EMBO Journal 20:6937-6945.
[0207] [40] Maiden et al. (1998) PNAS USA 95:3140-3145.
[0208] [41] WO01/09350.
[0209] [42] WO02/062378.
[0210] [43] WO2004/014417.
[0211] [44] WO00/66741.
[0212] [45] WO99/57280
[0213] [46] U.S. Pat. No. 5,698,438.
[0214] [47] Perkins-Balding et al. (2003) Microbiology 149:3423-35.
[0215] [48] Masignani et al. (2003) J Exp Med 197:789-799.
[0216] [49] Welsch et al. (2004) J Immunol 172:5605-15.
[0217] [50] Hou et al. (2005) J Infect Dis 192(4): 580-90.
[0218] [51] WO03/063766.
[0219] [52] Fletcher et al. (2004) Infect Immun 72:2088-2100.
[0220] [53] Zhu et al. (2005) Infect Immun 73(10):6838-45.
[0221] [54] Cantini et al. (2006) J. Biol. Chem. 281:7220-7227
[0222] [55] WO2004/048404
[0223] [56] WO2009/104097.
[0224] [57] Martin et al. (1997) J Exp Med 185(7):1173-83.
[0225] [58] WO96/29412.
[0226] [59] WO01/55182.
[0227] [60] WO01/38350.
[0228] [61] WO00/23595.
[0229] [62] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.
[0230] [63] RIVM report 124001 004.
[0231] [64] RIVM report 000012 003.
[0232] [65] Vaccine Design . . . (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.
[0233] [66] WO01/30390.
[0234] [67] http://neisseria.org/nm/typing/mlst/
[0235] [68] Tettelin et al. (2000) Science 287:1809-1815.
[0236] [69] Pettersson et al. (1994) Microb Pathog 17(6):395-408.
[0237] [70] Welsch et al. (2002) Thirteenth International Pathogenic Neisseria Conference, Norwegian Institute of Public Health, Oslo, Norway; Sep. 1-6, 2002. Genome-derived antigen (GNA) 2132 elicits protective serum antibodies to groups B and C Neisseria meningitidis strains.
[0238] [71] Santos et al. (2002) Thirteenth International Pathogenic Neisseria Conference, Norwegian Institute of Public Health, Oslo, Norway; Sep. 1-6, 2002. Serum Bactericidal responses in rhesus macaques immunized with novel vaccines containing recombinant proteins derived from the genome of N. meningitidis.
[0239] [72] WO2007/000327.
[0240] [73] WO2007/071707
[0241] [74] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)
[0242] [75] Handbook of Experimental Immunology, Vols. I-IV (D. M, Weir and C. C. Blackwell, eds, 1986, Blackwell Scientific Publications)
[0243] [76] Sambrook et al. (2001) Molecular Cloning: A. Laboratory Manual, 3rd edition (Cold Spring Harbor Laboratory Press).
[0244] [77] Handbook of Surface and Colloidal Chemistry (Birdi, K. S, ed., CRC Press, 1997)
[0245] [78] Ausubel et al. (eds) (2002) Short protocols in molecular biology, 5th edition (Current Protocols).
[0246] [79] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., 1998, Academic Press)
[0247] [80] PCR (Introduction to Biotechniques Series), 2nd ed. (Newton & Graham eds., 1997, Springer Verlag)
[0248] [81] Geysen et al. (1984) PNAS USA 81:3998-4002.
[0249] [82] Carter (1994) Methods Mol Biol 36:207-23.
[0250] [83] Jameson, B A et al. 1988, CABIOS 4(1):181-186.
[0251] [84] Raddrizzani & Hammer (2000) Brief Bioinform 1(2):179-89.
[0252] [85] Bublil et al. (2007) Proteins 68(1):294-304.
[0253] [86] De Lalla et al. (1999) J. Immunol. 1.63:1725-29.
[0254] [87] Kwok et al. (2001) Trends Immunol 22:583-88.
[0255] [88] Brusic et al. (1998) Bioinformatics 14(2):121-30
[0256] [89] Meister at al (1995) Vaccine 13(6):581-91.
[0257] [90] Roberts et al. (1996) AIDS Res Hum Retroviruses 12(7):593-610.
[0258] [91] Maksyutov & Zagrebelnaya (1993) Comput Appl Biosci 9(3):291-7.
[0259] [92] Feller & de la Cruz (1991) Nature 349(6311:720-1.
[0260] [93] Hopp (1993) Peptide Research 6:183-190.
[0261] [94] Welling et al. (1985) FEBS Lett. 188:215-218.
[0262] [95] Davenport et al. (1995) Immunogenetics 42:392-297.
[0263] [96] Tsurui & Takahashi (2007) J Pharmacol Sci. 105(4):299-316.
[0264] [97] Tong et al. (2007) Brief Bioinform. 8(2):96-108.
[0265] [98] Schirle et al. (2001) J Immunol Methods. 257(1-2):1-16.
[0266] [99] Chen et al. (2007) Amino Acids 33(3):423-8.
[0267] [100] Current Protocols in Molecular Biology (F. M. Ausubel et al., eds., 1987) Supplement 30
[0268] [101] Smith & Waterman (1981) Adv. Appl. Math. 2: 482-489.
Sequence CWU
1
1
251248PRTNeisseria meningitidis 1Val Ala Ala Asp Ile Gly Ala Gly Leu Ala
Asp Ala Leu Thr Ala Pro1 5 10
15Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser
20 25 30Val Arg Lys Asn Glu Lys
Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40
45Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys
Asn Asp 50 55 60Lys Val Ser Arg Phe
Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln65 70
75 80Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln
Val Tyr Lys Gln Ser His 85 90
95Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His
100 105 110Ser Gly Lys Met Val
Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala 115
120 125Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly
Gly Arg Ala Thr 130 135 140Tyr Arg Gly
Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr145
150 155 160Tyr Thr Ile Asp Phe Ala Ala
Lys Gln Gly Asn Gly Lys Ile Glu His 165
170 175Leu Lys Ser Pro Glu Leu Asn Val Asp Leu Ala Ala
Ala Asp Ile Lys 180 185 190Pro
Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn 195
200 205Gln Ala Glu Lys Gly Ser Tyr Ser Leu
Gly Ile Phe Gly Gly Lys Ala 210 215
220Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg225
230 235 240His Ile Gly Leu
Ala Ala Lys Gln 2452247PRTNeisseria meningitidis 2Val Ala
Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro1 5
10 15Leu Asp His Lys Asp Lys Ser Leu
Gln Ser Leu Thr Leu Asp Gln Ser 20 25
30Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu
Lys 35 40 45Thr Tyr Gly Asn Gly
Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55
60Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp
Gly Gln65 70 75 80Leu
Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His
85 90 95Ser Ala Val Val Ala Leu Gln
Ile Glu Lys Ile Asn Asn Pro Asp Lys 100 105
110Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly
Leu Gly 115 120 125Gly Glu His Thr
Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr 130
135 140His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly
Lys Leu Thr Tyr145 150 155
160Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu
165 170 175Lys Thr Pro Glu Gln
Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala 180
185 190Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr
Arg Tyr Gly Ser 195 200 205Glu Glu
Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln 210
215 220Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly
Glu Lys Val His Glu225 230 235
240Ile Gly Ile Ala Gly Lys Gln 2453250PRTNeisseria
meningitidis 3Val Ala Ala Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala
Pro1 5 10 15Leu Asp His
Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser 20
25 30Ile Pro Gln Asn Gly Thr Leu Thr Leu Ser
Ala Gln Gly Ala Glu Lys 35 40
45Thr Phe Lys Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu 50
55 60Lys Asn Asp Lys Ile Ser Arg Phe Asp
Phe Val Gln Lys Ile Glu Val65 70 75
80Asp Gly Gln Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile
Tyr Lys 85 90 95Gln Asn
His Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn 100
105 110Pro Asp Lys Thr Asp Ser Leu Ile Asn
Gln Arg Ser Phe Leu Val Ser 115 120
125Gly Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys
130 135 140Ala Glu Tyr His Gly Lys Ala
Phe Ser Ser Asp Asp Pro Asn Gly Arg145 150
155 160Leu His Tyr Ser Ile Asp Phe Thr Lys Lys Gln Gly
Tyr Gly Arg Ile 165 170
175Glu His Leu Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu
180 185 190Leu Lys Ala Asp Glu Lys
Ser His Ala Val Ile Leu Gly Asp Thr Arg 195 200
205Tyr Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe
Gly Asp 210 215 220Arg Ala Gln Glu Ile
Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys225 230
235 240Val His Glu Ile Gly Ile Ala Gly Lys Gln
245 2504644PRTArtificial SequenceHybrid
meningococcal antigen 4Met Ala Ser Pro Asp Val Lys Ser Ala Asp Thr Leu
Ser Lys Pro Ala1 5 10
15Ala Pro Val Val Ser Glu Lys Glu Thr Glu Ala Lys Glu Asp Ala Pro
20 25 30Gln Ala Gly Ser Gln Gly Gln
Gly Ala Pro Ser Ala Gln Gly Gly Gln 35 40
45Asp Met Ala Ala Val Ser Glu Glu Asn Thr Gly Asn Gly Gly Ala
Ala 50 55 60Ala Thr Asp Lys Pro Lys
Asn Glu Asp Glu Gly Ala Gln Asn Asp Met65 70
75 80Pro Gln Asn Ala Ala Asp Thr Asp Ser Leu Thr
Pro Asn His Thr Pro 85 90
95Ala Ser Asn Met Pro Ala Gly Asn Met Glu Asn Gln Ala Pro Asp Ala
100 105 110Gly Glu Ser Glu Gln Pro
Ala Asn Gln Pro Asp Met Ala Asn Thr Ala 115 120
125Asp Gly Met Gln Gly Asp Asp Pro Ser Ala Gly Gly Glu Asn
Ala Gly 130 135 140Asn Thr Ala Ala Gln
Gly Thr Asn Gln Ala Glu Asn Asn Gln Thr Ala145 150
155 160Gly Ser Gln Asn Pro Ala Ser Ser Thr Asn
Pro Ser Ala Thr Asn Ser 165 170
175Gly Gly Asp Phe Gly Arg Thr Asn Val Gly Asn Ser Val Val Ile Asp
180 185 190Gly Pro Ser Gln Asn
Ile Thr Leu Thr His Cys Lys Gly Asp Ser Cys 195
200 205Ser Gly Asn Asn Phe Leu Asp Glu Glu Val Gln Leu
Lys Ser Glu Phe 210 215 220Glu Lys Leu
Ser Asp Ala Asp Lys Ile Ser Asn Tyr Lys Lys Asp Gly225
230 235 240Lys Asn Asp Gly Lys Asn Asp
Lys Phe Val Gly Leu Val Ala Asp Ser 245
250 255Val Gln Met Lys Gly Ile Asn Gln Tyr Ile Ile Phe
Tyr Lys Pro Lys 260 265 270Pro
Thr Ser Phe Ala Arg Phe Arg Arg Ser Ala Arg Ser Arg Arg Ser 275
280 285Leu Pro Ala Glu Met Pro Leu Ile Pro
Val Asn Gln Ala Asp Thr Leu 290 295
300Ile Val Asp Gly Glu Ala Val Ser Leu Thr Gly His Ser Gly Asn Ile305
310 315 320Phe Ala Pro Glu
Gly Asn Tyr Arg Tyr Leu Thr Tyr Gly Ala Glu Lys 325
330 335Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val
Gln Gly Glu Pro Ser Lys 340 345
350Gly Glu Met Leu Ala Gly Thr Ala Val Tyr Asn Gly Glu Val Leu His
355 360 365Phe His Thr Glu Asn Gly Arg
Pro Ser Pro Ser Arg Gly Arg Phe Ala 370 375
380Ala Lys Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile Asp
Ser385 390 395 400Gly Asp
Gly Leu His Met Gly Thr Gln Lys Phe Lys Ala Ala Ile Asp
405 410 415Gly Asn Gly Phe Lys Gly Thr
Trp Thr Glu Asn Gly Gly Gly Asp Val 420 425
430Ser Gly Lys Phe Tyr Gly Pro Ala Gly Glu Glu Val Ala Gly
Lys Tyr 435 440 445Ser Tyr Arg Pro
Thr Asp Ala Glu Lys Gly Gly Phe Gly Val Phe Ala 450
455 460Gly Lys Lys Glu Gln Asp Gly Ser Gly Gly Gly Gly
Ala Thr Tyr Lys465 470 475
480Val Asp Glu Tyr His Ala Asn Ala Arg Phe Ala Ile Asp His Phe Asn
485 490 495Thr Ser Thr Asn Val
Gly Gly Phe Tyr Gly Leu Thr Gly Ser Val Glu 500
505 510Phe Asp Gln Ala Lys Arg Asp Gly Lys Ile Asp Ile
Thr Ile Pro Val 515 520 525Ala Asn
Leu Gln Ser Gly Ser Gln His Phe Thr Asp His Leu Lys Ser 530
535 540Ala Asp Ile Phe Asp Ala Ala Gln Tyr Pro Asp
Ile Arg Phe Val Ser545 550 555
560Thr Lys Phe Asn Phe Asn Gly Lys Lys Leu Val Ser Val Asp Gly Asn
565 570 575Leu Thr Met His
Gly Lys Thr Ala Pro Val Lys Leu Lys Ala Glu Lys 580
585 590Phe Asn Cys Tyr Gln Ser Pro Met Ala Lys Thr
Glu Val Cys Gly Gly 595 600 605Asp
Phe Ser Thr Thr Ile Asp Arg Thr Lys Trp Gly Val Asp Tyr Leu 610
615 620Val Asn Val Gly Met Thr Lys Ser Val Arg
Ile Asp Ile Gln Ile Glu625 630 635
640Ala Ala Lys Gln5434PRTArtificial SequenceHybrid meningococcal
antigen 5Met Val Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala1
5 10 15Val Asp Arg Arg
Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala 20
25 30Leu Arg Ile Glu Thr Thr Ala Arg Ser Tyr Leu
Arg Gln Asn Asn Gln 35 40 45Thr
Lys Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His 50
55 60Leu Leu Leu Leu Gly Gln Val Ala Thr Glu
Gly Glu Lys Gln Phe Val65 70 75
80Gly Gln Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn
Tyr 85 90 95Ile Thr Val
Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp 100
105 110Thr Trp Asn Thr Ser Lys Val Arg Ala Thr
Leu Leu Gly Ile Ser Pro 115 120
125Ala Thr Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr 130
135 140Val Met Gly Ile Leu Thr Pro Glu
Glu Gln Ala Gln Ile Thr Gln Lys145 150
155 160Val Ser Thr Thr Val Gly Val Gln Lys Val Ile Thr
Leu Tyr Gln Asn 165 170
175Tyr Val Gln Arg Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly
180 185 190Ala Gly Leu Ala Asp Ala
Leu Thr Ala Pro Leu Asp His Lys Asp Lys 195 200
205Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn
Glu Lys 210 215 220Leu Lys Leu Ala Ala
Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp225 230
235 240Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp
Lys Val Ser Arg Phe Asp 245 250
255Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser
260 265 270Gly Glu Phe Gln Val
Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe 275
280 285Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly
Lys Met Val Ala 290 295 300Lys Arg Gln
Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe305
310 315 320Asp Lys Leu Pro Glu Gly Gly
Arg Ala Thr Tyr Arg Gly Thr Ala Phe 325
330 335Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr
Ile Asp Phe Ala 340 345 350Ala
Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu 355
360 365Asn Val Asp Leu Ala Ala Ala Asp Ile
Lys Pro Asp Gly Lys Arg His 370 375
380Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser385
390 395 400Tyr Ser Leu Gly
Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser 405
410 415Ala Glu Val Lys Thr Val Asn Gly Ile Arg
His Ile Gly Leu Ala Ala 420 425
430Lys Gln6327PRTNeisseria meningitidis 6Ala Thr Asn Asp Asp Asp Val Lys
Lys Ala Ala Thr Val Ala Ile Ala1 5 10
15Ala Ala Tyr Asn Asn Gly Gln Glu Ile Asn Gly Phe Lys Ala
Gly Glu 20 25 30Thr Ile Tyr
Asp Ile Asp Glu Asp Gly Thr Ile Thr Lys Lys Asp Ala 35
40 45Thr Ala Ala Asp Val Glu Ala Asp Asp Phe Lys
Gly Leu Gly Leu Lys 50 55 60Lys Val
Val Thr Asn Leu Thr Lys Thr Val Asn Glu Asn Lys Gln Asn65
70 75 80Val Asp Ala Lys Val Lys Ala
Ala Glu Ser Glu Ile Glu Lys Leu Thr 85 90
95Thr Lys Leu Ala Asp Thr Asp Ala Ala Leu Ala Asp Thr
Asp Ala Ala 100 105 110Leu Asp
Ala Thr Thr Asn Ala Leu Asn Lys Leu Gly Glu Asn Ile Thr 115
120 125Thr Phe Ala Glu Glu Thr Lys Thr Asn Ile
Val Lys Ile Asp Glu Lys 130 135 140Leu
Glu Ala Val Ala Asp Thr Val Asp Lys His Ala Glu Ala Phe Asn145
150 155 160Asp Ile Ala Asp Ser Leu
Asp Glu Thr Asn Thr Lys Ala Asp Glu Ala 165
170 175Val Lys Thr Ala Asn Glu Ala Lys Gln Thr Ala Glu
Glu Thr Lys Gln 180 185 190Asn
Val Asp Ala Lys Val Lys Ala Ala Glu Thr Ala Ala Gly Lys Ala 195
200 205Glu Ala Ala Ala Gly Thr Ala Asn Thr
Ala Ala Asp Lys Ala Glu Ala 210 215
220Val Ala Ala Lys Val Thr Asp Ile Lys Ala Asp Ile Ala Thr Asn Lys225
230 235 240Asp Asn Ile Ala
Lys Lys Ala Asn Ser Ala Asp Val Tyr Thr Arg Glu 245
250 255Glu Ser Asp Ser Lys Phe Val Arg Ile Asp
Gly Leu Asn Ala Thr Thr 260 265
270Glu Lys Leu Asp Thr Arg Leu Ala Ser Ala Glu Lys Ser Ile Ala Asp
275 280 285His Asp Thr Arg Leu Asn Gly
Leu Asp Lys Thr Val Ser Asp Leu Arg 290 295
300Lys Glu Thr Arg Gln Gly Leu Ala Glu Gln Ala Ala Leu Ser Gly
Leu305 310 315 320Phe Gln
Pro Tyr Asn Val Gly 3257792PRTNeisseria meningitidis 7Met
Lys Pro Leu Gln Met Leu Pro Ile Ala Ala Leu Val Gly Ser Ile1
5 10 15Phe Gly Asn Pro Val Leu Ala
Ala Asp Glu Ala Ala Thr Glu Thr Thr 20 25
30Pro Val Lys Ala Glu Ile Lys Ala Val Arg Val Lys Gly Gln
Arg Asn 35 40 45Ala Pro Ala Ala
Val Glu Arg Val Asn Leu Asn Arg Ile Lys Gln Glu 50 55
60Met Ile Arg Asp Asn Lys Asp Leu Val Arg Tyr Ser Thr
Asp Val Gly65 70 75
80Leu Ser Asp Ser Gly Arg His Gln Lys Gly Phe Ala Val Arg Gly Val
85 90 95Glu Gly Asn Arg Val Gly
Val Ser Ile Asp Gly Val Asn Leu Pro Asp 100
105 110Ser Glu Glu Asn Ser Leu Tyr Ala Arg Tyr Gly Asn
Phe Asn Ser Ser 115 120 125Arg Leu
Ser Ile Asp Pro Glu Leu Val Arg Asn Ile Glu Ile Val Lys 130
135 140Gly Ala Asp Ser Phe Asn Thr Gly Ser Gly Ala
Leu Gly Gly Gly Val145 150 155
160Asn Tyr Gln Thr Leu Gln Gly Arg Asp Leu Leu Leu Asp Asp Arg Gln
165 170 175Phe Gly Val Met
Met Lys Asn Gly Tyr Ser Thr Arg Asn Arg Glu Trp 180
185 190Thr Asn Thr Leu Gly Phe Gly Val Ser Asn Asp
Arg Val Asp Ala Ala 195 200 205Leu
Leu Tyr Ser Gln Arg Arg Gly His Glu Thr Glu Ser Ala Gly Asn 210
215 220Arg Gly Tyr Ala Val Glu Gly Glu Gly Ser
Gly Ala Asn Ile Arg Gly225 230 235
240Ser Ala Arg Gly Ile Pro Asp Ser Ser Lys His Lys Tyr Asn His
His 245 250 255Ala Leu Gly
Lys Ile Ala Tyr Gln Ile Asn Asp Asn His Arg Ile Gly 260
265 270Ala Ser Leu Asn Gly Gln Gln Gly His Asn
Tyr Thr Val Glu Glu Ser 275 280
285Tyr Asn Leu Thr Ala Ser Ser Trp Arg Glu Ala Asp Asp Val Asn Arg 290
295 300Arg Arg Asn Ala Asn Leu Phe Tyr
Glu Trp Met Pro Asp Ser Asn Trp305 310
315 320Leu Ser Ser Leu Lys Ala Asp Phe Asp Tyr Gln Lys
Thr Lys Val Ala 325 330
335Ala Val Asn Asn Lys Gly Ser Phe Pro Met Asp Tyr Ser Thr Trp Thr
340 345 350Arg Asn Tyr Asn Gln Lys
Asp Leu Asp Glu Ile Tyr Asn Arg Ser Met 355 360
365Asp Thr Arg Phe Lys Arg Phe Thr Leu Arg Leu Asp Ser His
Pro Leu 370 375 380Gln Leu Gly Gly Gly
Arg His Arg Leu Ser Phe Lys Thr Phe Val Ser385 390
395 400Arg Arg Asp Phe Glu Asn Leu Asn Arg Asp
Asp Tyr Tyr Phe Ser Gly 405 410
415Arg Val Val Arg Thr Thr Ser Ser Ile Gln His Pro Val Lys Thr Thr
420 425 430Asn Tyr Gly Phe Ser
Leu Ser Asp Gln Ile Gln Trp Asn Asp Val Phe 435
440 445Ser Ser Arg Ala Gly Ile Arg Tyr Asp His Thr Lys
Met Thr Pro Gln 450 455 460Glu Leu Asn
Ala Glu Cys His Ala Cys Asp Lys Thr Pro Pro Ala Ala465
470 475 480Asn Thr Tyr Lys Gly Trp Ser
Gly Phe Val Gly Leu Ala Ala Gln Leu 485
490 495Asn Gln Ala Trp Arg Val Gly Tyr Asp Ile Thr Ser
Gly Tyr Arg Val 500 505 510Pro
Asn Ala Ser Glu Val Tyr Phe Thr Tyr Asn His Gly Ser Gly Asn 515
520 525Trp Leu Pro Asn Pro Asn Leu Lys Ala
Glu Arg Ser Thr Thr His Thr 530 535
540Leu Ser Leu Gln Gly Arg Ser Glu Lys Gly Met Leu Asp Ala Asn Leu545
550 555 560Tyr Gln Ser Asn
Tyr Arg Asn Phe Leu Ser Glu Glu Gln Lys Leu Thr 565
570 575Thr Ser Gly Thr Pro Gly Cys Thr Glu Glu
Asn Ala Tyr Tyr Gly Ile 580 585
590Cys Ser Asp Pro Tyr Lys Glu Lys Leu Asp Trp Gln Met Lys Asn Ile
595 600 605Asp Lys Ala Arg Ile Arg Gly
Ile Glu Leu Thr Gly Arg Leu Asn Val 610 615
620Asp Lys Val Ala Ser Phe Val Pro Glu Gly Trp Lys Leu Phe Gly
Ser625 630 635 640Leu Gly
Tyr Ala Lys Ser Lys Leu Ser Gly Asp Asn Ser Leu Leu Ser
645 650 655Thr Gln Pro Leu Lys Val Ile
Ala Gly Ile Asp Tyr Glu Ser Pro Ser 660 665
670Glu Lys Trp Gly Val Phe Ser Arg Leu Thr Tyr Leu Gly Ala
Lys Lys 675 680 685Val Lys Asp Ala
Gln Tyr Thr Val Tyr Glu Asn Lys Gly Trp Gly Thr 690
695 700Pro Leu Gln Lys Lys Val Lys Asp Tyr Pro Trp Leu
Asn Lys Ser Ala705 710 715
720Tyr Val Phe Asp Met Tyr Gly Phe Tyr Lys Pro Ala Lys Asn Leu Thr
725 730 735Leu Arg Ala Gly Val
Tyr Asn Leu Phe Asn Arg Lys Tyr Thr Thr Trp 740
745 750Asp Ser Leu Arg Gly Leu Tyr Ser Tyr Ser Thr Thr
Asn Ala Val Asp 755 760 765Arg Asp
Gly Lys Gly Leu Asp Arg Tyr Arg Ala Pro Gly Arg Asn Tyr 770
775 780Ala Val Ser Leu Glu Trp Lys Phe785
7908793PRTNeisseria meningitidis 8Met Lys Pro Leu Gln Met Leu Pro
Ile Ala Ala Leu Val Gly Ser Ile1 5 10
15Phe Gly Asn Pro Val Phe Ala Ala Asp Glu Ala Ala Thr Glu
Thr Thr 20 25 30Pro Val Lys
Ala Glu Val Lys Ala Val Arg Val Lys Gly Gln Arg Asn 35
40 45Ala Pro Ala Ala Val Glu Arg Val Asn Leu Asn
Arg Ile Lys Gln Glu 50 55 60Met Ile
Arg Asp Asn Lys Asp Leu Val Arg Tyr Ser Thr Asp Val Gly65
70 75 80Leu Ser Asp Ser Gly Arg His
Gln Lys Gly Phe Ala Val Arg Gly Val 85 90
95Glu Gly Asn Arg Val Gly Val Ser Ile Asp Gly Val Asn
Leu Pro Asp 100 105 110Ser Glu
Glu Asn Ser Leu Tyr Ala Arg Tyr Gly Asn Phe Asn Ser Ser 115
120 125Arg Leu Ser Ile Asp Pro Glu Leu Val Arg
Asn Ile Asp Ile Val Lys 130 135 140Gly
Ala Asp Ser Phe Asn Thr Gly Ser Gly Ala Leu Gly Gly Gly Val145
150 155 160Asn Tyr Gln Thr Leu Gln
Gly Arg Asp Leu Leu Leu Pro Glu Arg Gln 165
170 175Phe Gly Val Met Met Lys Asn Gly Tyr Ser Thr Arg
Asn Arg Glu Trp 180 185 190Thr
Asn Thr Leu Gly Phe Gly Val Ser Asn Asp Arg Val Asp Ala Ala 195
200 205Leu Leu Tyr Ser Gln Arg Arg Gly His
Glu Thr Glu Ser Ala Gly Lys 210 215
220Arg Gly Tyr Pro Val Glu Gly Ala Gly Ser Gly Ala Asn Ile Arg Gly225
230 235 240Ser Ala Arg Gly
Ile Pro Asp Pro Ser Gln His Lys Tyr Asn His His 245
250 255Ala Leu Gly Lys Ile Ala Tyr Gln Ile Asn
Asp Asn His Arg Ile Gly 260 265
270Ala Ser Leu Asn Gly Gln Gln Gly His Asn Tyr Thr Val Glu Glu Ser
275 280 285Tyr Asn Leu Leu Ala Ser Tyr
Trp Arg Glu Ala Asp Asp Val Asn Arg 290 295
300Arg Arg Asn Thr Asn Leu Phe Tyr Glu Trp Thr Pro Glu Ser Asp
Arg305 310 315 320Leu Ser
Met Val Lys Ala Asp Val Asp Tyr Gln Lys Thr Lys Val Ser
325 330 335Ala Val Asn Tyr Lys Gly Ser
Phe Pro Ile Glu Asp Ser Ser Thr Leu 340 345
350Thr Arg Asn Tyr Asn Gln Lys Asp Leu Asp Glu Ile Tyr Asn
Arg Ser 355 360 365Met Asp Thr Arg
Phe Lys Arg Ile Thr Leu Arg Leu Asp Ser His Pro 370
375 380Leu Gln Leu Gly Gly Gly Arg His Arg Leu Ser Phe
Lys Thr Phe Ala385 390 395
400Ser Arg Arg Asp Phe Glu Asn Leu Asn Arg Asp Asp Tyr Tyr Phe Ser
405 410 415Gly Arg Val Val Arg
Thr Thr Ser Ser Ile Gln His Pro Val Lys Thr 420
425 430Thr Asn Tyr Gly Phe Ser Leu Ser Asp Gln Ile Gln
Trp Asn Asp Val 435 440 445Phe Ser
Ser Arg Ala Gly Ile Arg Tyr Asp His Thr Lys Met Thr Pro 450
455 460Gln Glu Leu Asn Ala Glu Cys His Ala Cys Asp
Lys Thr Pro Pro Ala465 470 475
480Ala Asn Thr Tyr Lys Gly Trp Ser Gly Phe Val Gly Leu Ala Ala Gln
485 490 495Leu Asn Gln Ala
Trp Arg Val Gly Tyr Asp Ile Thr Ser Gly Tyr Arg 500
505 510Val Pro Asn Ala Ser Glu Val Tyr Phe Thr Tyr
Asn His Gly Ser Gly 515 520 525Asn
Trp Leu Pro Asn Pro Asn Leu Lys Ala Glu Arg Thr Thr Thr His 530
535 540Thr Leu Ser Leu Gln Gly Arg Ser Glu Lys
Gly Thr Leu Asp Ala Asn545 550 555
560Leu Tyr Gln Ser Asn Tyr Arg Asn Phe Leu Ser Glu Glu Gln Lys
Leu 565 570 575Thr Thr Ser
Gly Asp Val Ser Cys Thr Gln Met Asn Tyr Tyr Tyr Gly 580
585 590Met Cys Ser Asn Pro Tyr Ser Glu Lys Leu
Glu Trp Gln Met Gln Asn 595 600
605Ile Asp Lys Ala Arg Ile Arg Gly Ile Glu Leu Thr Gly Arg Leu Asn 610
615 620Val Asp Lys Val Ala Ser Phe Val
Pro Glu Gly Trp Lys Leu Phe Gly625 630
635 640Ser Leu Gly Tyr Ala Lys Ser Lys Leu Ser Gly Asp
Asn Ser Leu Leu 645 650
655Ser Thr Gln Pro Leu Lys Val Ile Ala Gly Ile Asp Tyr Glu Ser Pro
660 665 670Ser Glu Lys Trp Gly Val
Phe Ser Arg Leu Thr Tyr Leu Gly Ala Lys 675 680
685Lys Val Lys Asp Ala Gln Tyr Thr Val Tyr Glu Asn Lys Gly
Trp Gly 690 695 700Thr Pro Leu Gln Lys
Lys Val Lys Asp Tyr Pro Trp Leu Asn Lys Ser705 710
715 720Ala Tyr Val Phe Asp Met Tyr Gly Phe Tyr
Lys Pro Val Lys Asn Leu 725 730
735Thr Leu Arg Ala Gly Val Tyr Asn Val Phe Asn Arg Lys Tyr Thr Thr
740 745 750Trp Asp Ser Leu Arg
Gly Leu Tyr Ser Tyr Ser Thr Thr Asn Ser Val 755
760 765Asp Arg Asp Gly Lys Gly Leu Asp Arg Tyr Arg Ala
Pro Ser Arg Asn 770 775 780Tyr Ala Val
Ser Leu Glu Trp Lys Phe785 7909488PRTNeisseria
meningitidis 9Met Phe Lys Arg Ser Val Ile Ala Met Ala Cys Ile Phe Ala Leu
Ser1 5 10 15Ala Cys Gly
Gly Gly Gly Gly Gly Ser Pro Asp Val Lys Ser Ala Asp 20
25 30Thr Leu Ser Lys Pro Ala Ala Pro Val Val
Ser Glu Lys Glu Thr Glu 35 40
45Ala Lys Glu Asp Ala Pro Gln Ala Gly Ser Gln Gly Gln Gly Ala Pro 50
55 60Ser Ala Gln Gly Ser Gln Asp Met Ala
Ala Val Ser Glu Glu Asn Thr65 70 75
80Gly Asn Gly Gly Ala Val Thr Ala Asp Asn Pro Lys Asn Glu
Asp Glu 85 90 95Val Ala
Gln Asn Asp Met Pro Gln Asn Ala Ala Gly Thr Asp Ser Ser 100
105 110Thr Pro Asn His Thr Pro Asp Pro Asn
Met Leu Ala Gly Asn Met Glu 115 120
125Asn Gln Ala Thr Asp Ala Gly Glu Ser Ser Gln Pro Ala Asn Gln Pro
130 135 140Asp Met Ala Asn Ala Ala Asp
Gly Met Gln Gly Asp Asp Pro Ser Ala145 150
155 160Gly Gly Gln Asn Ala Gly Asn Thr Ala Ala Gln Gly
Ala Asn Gln Ala 165 170
175Gly Asn Asn Gln Ala Ala Gly Ser Ser Asp Pro Ile Pro Ala Ser Asn
180 185 190Pro Ala Pro Ala Asn Gly
Gly Ser Asn Phe Gly Arg Val Asp Leu Ala 195 200
205Asn Gly Val Leu Ile Asp Gly Pro Ser Gln Asn Ile Thr Leu
Thr His 210 215 220Cys Lys Gly Asp Ser
Cys Ser Gly Asn Asn Phe Leu Asp Glu Glu Val225 230
235 240Gln Leu Lys Ser Glu Phe Glu Lys Leu Ser
Asp Ala Asp Lys Ile Ser 245 250
255Asn Tyr Lys Lys Asp Gly Lys Asn Asp Lys Phe Val Gly Leu Val Ala
260 265 270Asp Ser Val Gln Met
Lys Gly Ile Asn Gln Tyr Ile Ile Phe Tyr Lys 275
280 285Pro Lys Pro Thr Ser Phe Ala Arg Phe Arg Arg Ser
Ala Arg Ser Arg 290 295 300Arg Ser Leu
Pro Ala Glu Met Pro Leu Ile Pro Val Asn Gln Ala Asp305
310 315 320Thr Leu Ile Val Asp Gly Glu
Ala Val Ser Leu Thr Gly His Ser Gly 325
330 335Asn Ile Phe Ala Pro Glu Gly Asn Tyr Arg Tyr Leu
Thr Tyr Gly Ala 340 345 350Glu
Lys Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val Gln Gly Glu Pro 355
360 365Ala Lys Gly Glu Met Leu Ala Gly Ala
Ala Val Tyr Asn Gly Glu Val 370 375
380Leu His Phe His Thr Glu Asn Gly Arg Pro Tyr Pro Thr Arg Gly Arg385
390 395 400Phe Ala Ala Lys
Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile 405
410 415Asp Ser Gly Asp Asp Leu His Met Gly Thr
Gln Lys Phe Lys Ala Ala 420 425
430Ile Asp Gly Asn Gly Phe Lys Gly Thr Trp Thr Glu Asn Gly Ser Gly
435 440 445Asp Val Ser Gly Lys Phe Tyr
Gly Pro Ala Gly Glu Glu Val Ala Gly 450 455
460Lys Tyr Ser Tyr Arg Pro Thr Asp Ala Glu Lys Gly Gly Phe Gly
Val465 470 475 480Phe Ala
Gly Lys Lys Glu Gln Asp 48510364PRTNeisseria meningitidis
10Met Ser Met Lys His Phe Pro Ser Lys Val Leu Thr Thr Ala Ile Leu1
5 10 15Ala Thr Phe Cys Ser Gly
Ala Leu Ala Ala Thr Ser Asp Asp Asp Val 20 25
30Lys Lys Ala Ala Thr Val Ala Ile Val Ala Ala Tyr Asn
Asn Gly Gln 35 40 45Glu Ile Asn
Gly Phe Lys Ala Gly Glu Thr Ile Tyr Asp Ile Gly Glu 50
55 60Asp Gly Thr Ile Thr Gln Lys Asp Ala Thr Ala Ala
Asp Val Glu Ala65 70 75
80Asp Asp Phe Lys Gly Leu Gly Leu Lys Lys Val Val Thr Asn Leu Thr
85 90 95Lys Thr Val Asn Glu Asn
Lys Gln Asn Val Asp Ala Lys Val Lys Ala 100
105 110Ala Glu Ser Glu Ile Glu Lys Leu Thr Thr Lys Leu
Ala Asp Thr Asp 115 120 125Ala Ala
Leu Ala Asp Thr Asp Ala Ala Leu Asp Glu Thr Thr Asn Ala 130
135 140Leu Asn Lys Leu Gly Glu Asn Ile Thr Thr Phe
Ala Glu Glu Thr Lys145 150 155
160Thr Asn Ile Val Lys Ile Asp Glu Lys Leu Glu Ala Val Ala Asp Thr
165 170 175Val Asp Lys His
Ala Glu Ala Phe Asn Asp Ile Ala Asp Ser Leu Asp 180
185 190Glu Thr Asn Thr Lys Ala Asp Glu Ala Val Lys
Thr Ala Asn Glu Ala 195 200 205Lys
Gln Thr Ala Glu Glu Thr Lys Gln Asn Val Asp Ala Lys Val Lys 210
215 220Ala Ala Glu Thr Ala Ala Gly Lys Ala Glu
Ala Ala Ala Gly Thr Ala225 230 235
240Asn Thr Ala Ala Asp Lys Ala Glu Ala Val Ala Ala Lys Val Thr
Asp 245 250 255Ile Lys Ala
Asp Ile Ala Thr Asn Lys Ala Asp Ile Ala Lys Asn Ser 260
265 270Ala Arg Ile Asp Ser Leu Asp Lys Asn Val
Ala Asn Leu Arg Lys Glu 275 280
285Thr Arg Gln Gly Leu Ala Glu Gln Ala Ala Leu Ser Gly Leu Phe Gln 290
295 300Pro Tyr Asn Val Gly Arg Phe Asn
Val Thr Ala Ala Val Gly Gly Tyr305 310
315 320Lys Ser Glu Ser Ala Val Ala Ile Gly Thr Gly Phe
Arg Phe Thr Glu 325 330
335Asn Phe Ala Ala Lys Ala Gly Val Ala Val Gly Thr Ser Ser Gly Ser
340 345 350Ser Ala Ala Tyr His Val
Gly Val Asn Tyr Glu Trp 355 36011174PRTNeisseria
meningitidis 11Met Lys Lys Ala Leu Ala Thr Leu Ile Ala Leu Ala Leu Pro
Ala Ala1 5 10 15Ala Leu
Ala Glu Gly Ala Ser Gly Phe Tyr Val Gln Ala Asp Ala Ala 20
25 30His Ala Lys Ala Ser Ser Ser Leu Gly
Ser Ala Lys Gly Phe Ser Pro 35 40
45Arg Ile Ser Ala Gly Tyr Arg Ile Asn Asp Leu Arg Phe Ala Val Asp 50
55 60Tyr Thr Arg Tyr Lys Asn Tyr Lys Ala
Pro Ser Thr Asp Phe Lys Leu65 70 75
80Tyr Ser Ile Gly Ala Ser Ala Ile Tyr Asp Phe Asp Thr Gln
Ser Pro 85 90 95Val Lys
Pro Tyr Leu Gly Ala Arg Leu Ser Leu Asn Arg Ala Ser Val 100
105 110Asp Leu Gly Gly Ser Asp Ser Phe Ser
Gln Thr Ser Ile Gly Leu Gly 115 120
125Val Leu Thr Gly Val Ser Tyr Ala Val Thr Pro Asn Val Asp Leu Asp
130 135 140Ala Gly Tyr Arg Tyr Asn Tyr
Ile Gly Lys Val Asn Thr Val Lys Asn145 150
155 160Val Arg Ser Gly Glu Leu Ser Ala Gly Val Arg Val
Lys Phe 165 17012591PRTNeisseria
meningitidis 12Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn
Ala Trp1 5 10 15Val Val
Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20
25 30Thr Val Lys Thr Ala Val Leu Ala Thr
Leu Leu Phe Ala Thr Val Gln 35 40
45Ala Ser Ala Asn Asn Glu Glu Gln Glu Glu Asp Leu Tyr Leu Asp Pro 50
55 60Val Gln Arg Thr Val Ala Val Leu Ile
Val Asn Ser Asp Lys Glu Gly65 70 75
80Thr Gly Glu Lys Glu Lys Val Glu Glu Asn Ser Asp Trp Ala
Val Tyr 85 90 95Phe Asn
Glu Lys Gly Val Leu Thr Ala Arg Glu Ile Thr Leu Lys Ala 100
105 110Gly Asp Asn Leu Lys Ile Lys Gln Asn
Gly Thr Asn Phe Thr Tyr Ser 115 120
125Leu Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Gly Thr Glu Lys Leu
130 135 140Ser Phe Ser Ala Asn Gly Asn
Lys Val Asn Ile Thr Ser Asp Thr Lys145 150
155 160Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn
Gly Asp Thr Thr 165 170
175Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Leu Asn
180 185 190Thr Gly Ala Thr Thr Asn
Val Thr Asn Asp Asn Val Thr Asp Asp Glu 195 200
205Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly
Trp Asn 210 215 220Ile Lys Gly Val Lys
Pro Gly Thr Thr Ala Ser Asp Asn Val Asp Phe225 230
235 240Val Arg Thr Tyr Asp Thr Val Glu Phe Leu
Ser Ala Asp Thr Lys Thr 245 250
255Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Lys Thr Glu Val
260 265 270Lys Ile Gly Ala Lys
Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275
280 285Val Thr Gly Lys Asp Lys Gly Glu Asn Gly Ser Ser
Thr Asp Glu Gly 290 295 300Glu Gly Leu
Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala305
310 315 320Gly Trp Arg Met Lys Thr Thr
Thr Ala Asn Gly Gln Thr Gly Gln Ala 325
330 335Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val
Thr Phe Ala Ser 340 345 350Gly
Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln Gly Asn Ile 355
360 365Thr Val Met Tyr Asp Val Asn Val Gly
Asp Ala Leu Asn Val Asn Gln 370 375
380Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala Val Ala Gly Ser385
390 395 400Ser Gly Lys Val
Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405
410 415Asp Glu Thr Val Asn Ile Asn Ala Gly Asn
Asn Ile Glu Ile Thr Arg 420 425
430Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser
435 440 445Ser Val Ser Leu Gly Ala Gly
Ala Asp Ala Pro Thr Leu Ser Val Asp 450 455
460Gly Asp Ala Leu Asn Val Gly Ser Lys Lys Asp Asn Lys Pro Val
Arg465 470 475 480Ile Thr
Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val Thr Asn Val
485 490 495Ala Gln Leu Lys Gly Val Ala
Gln Asn Leu Asn Asn Arg Ile Asp Asn 500 505
510Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala
Thr Ala 515 520 525Gly Leu Val Gln
Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly 530
535 540Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile
Gly Tyr Ser Ser545 550 555
560Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn
565 570 575Ser Arg Gly His Phe
Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp 580
585 590131457PRTNeisseria meningitidis 13Met Lys Thr Thr
Asp Lys Arg Thr Thr Glu Thr His Arg Lys Ala Pro1 5
10 15Lys Thr Gly Arg Ile Arg Phe Ser Pro Ala
Tyr Leu Ala Ile Cys Leu 20 25
30Ser Phe Gly Ile Leu Pro Gln Ala Trp Ala Gly His Thr Tyr Phe Gly
35 40 45Ile Asn Tyr Gln Tyr Tyr Arg Asp
Phe Ala Glu Asn Lys Gly Lys Phe 50 55
60Ala Val Gly Ala Lys Asp Ile Glu Val Tyr Asn Lys Lys Gly Glu Leu65
70 75 80Val Gly Lys Ser Met
Thr Lys Ala Pro Met Ile Asp Phe Ser Val Val 85
90 95Ser Arg Asn Gly Val Ala Ala Leu Val Gly Asp
Gln Tyr Ile Val Ser 100 105
110Val Ala His Asn Gly Gly Tyr Asn Asn Val Asp Phe Gly Ala Glu Gly
115 120 125Arg Asn Pro Asp Gln His Arg
Phe Thr Tyr Lys Ile Val Lys Arg Asn 130 135
140Asn Tyr Lys Ala Gly Thr Lys Gly His Pro Tyr Gly Gly Asp Tyr
His145 150 155 160Met Pro
Arg Leu His Lys Phe Val Thr Asp Ala Glu Pro Val Glu Met
165 170 175Thr Ser Tyr Met Asp Gly Arg
Lys Tyr Ile Asp Gln Asn Asn Tyr Pro 180 185
190Asp Arg Val Arg Ile Gly Ala Gly Arg Gln Tyr Trp Arg Ser
Asp Glu 195 200 205Asp Glu Pro Asn
Asn Arg Glu Ser Ser Tyr His Ile Ala Ser Ala Tyr 210
215 220Ser Trp Leu Val Gly Gly Asn Thr Phe Ala Gln Asn
Gly Ser Gly Gly225 230 235
240Gly Thr Val Asn Leu Gly Ser Glu Lys Ile Lys His Ser Pro Tyr Gly
245 250 255Phe Leu Pro Thr Gly
Gly Ser Phe Gly Asp Ser Gly Ser Pro Met Phe 260
265 270Ile Tyr Asp Ala Gln Lys Gln Lys Trp Leu Ile Asn
Gly Val Leu Gln 275 280 285Thr Gly
Asn Pro Tyr Ile Gly Lys Ser Asn Gly Phe Gln Leu Val Arg 290
295 300Lys Asp Trp Phe Tyr Asp Glu Ile Phe Ala Gly
Asp Thr His Ser Val305 310 315
320Phe Tyr Glu Pro Arg Gln Asn Gly Lys Tyr Ser Phe Asn Asp Asp Asn
325 330 335Asn Gly Thr Gly
Lys Ile Asn Ala Lys His Glu His Asn Ser Leu Pro 340
345 350Asn Arg Leu Lys Thr Arg Thr Val Gln Leu Phe
Asn Val Ser Leu Ser 355 360 365Glu
Thr Ala Arg Glu Pro Val Tyr His Ala Ala Gly Gly Val Asn Ser 370
375 380Tyr Arg Pro Arg Leu Asn Asn Gly Glu Asn
Ile Ser Phe Ile Asp Glu385 390 395
400Gly Lys Gly Glu Leu Ile Leu Thr Ser Asn Ile Asn Gln Gly Ala
Gly 405 410 415Gly Leu Tyr
Phe Gln Gly Asp Phe Thr Val Ser Pro Glu Asn Asn Glu 420
425 430Thr Trp Gln Gly Ala Gly Val His Ile Ser
Glu Asp Ser Thr Val Thr 435 440
445Trp Lys Val Asn Gly Val Ala Asn Asp Arg Leu Ser Lys Ile Gly Lys 450
455 460Gly Thr Leu His Val Gln Ala Lys
Gly Glu Asn Gln Gly Ser Ile Ser465 470
475 480Val Gly Asp Gly Thr Val Ile Leu Asp Gln Gln Ala
Asp Asp Lys Gly 485 490
495Lys Lys Gln Ala Phe Ser Glu Ile Gly Leu Val Ser Gly Arg Gly Thr
500 505 510Val Gln Leu Asn Ala Asp
Asn Gln Phe Asn Pro Asp Lys Leu Tyr Phe 515 520
525Gly Phe Arg Gly Gly Arg Leu Asp Leu Asn Gly His Ser Leu
Ser Phe 530 535 540His Arg Ile Gln Asn
Thr Asp Glu Gly Ala Met Ile Val Asn His Asn545 550
555 560Gln Asp Lys Glu Ser Thr Val Thr Ile Thr
Gly Asn Lys Asp Ile Ala 565 570
575Thr Thr Gly Asn Asn Asn Ser Leu Asp Ser Lys Lys Glu Ile Ala Tyr
580 585 590Asn Gly Trp Phe Gly
Glu Lys Asp Thr Thr Lys Thr Asn Gly Arg Leu 595
600 605Asn Leu Val Tyr Gln Pro Ala Ala Glu Asp Arg Thr
Leu Leu Leu Ser 610 615 620Gly Gly Thr
Asn Leu Asn Gly Asn Ile Thr Gln Thr Asn Gly Lys Leu625
630 635 640Phe Phe Ser Gly Arg Pro Thr
Pro His Ala Tyr Asn His Leu Asn Asp 645
650 655His Trp Ser Gln Lys Glu Gly Ile Pro Arg Gly Glu
Ile Val Trp Asp 660 665 670Asn
Asp Trp Ile Asn Arg Thr Phe Lys Ala Glu Asn Phe Gln Ile Lys 675
680 685Gly Gly Gln Ala Val Val Ser Arg Asn
Val Ala Lys Val Lys Gly Asp 690 695
700Trp His Leu Ser Asn His Ala Gln Ala Val Phe Gly Val Ala Pro His705
710 715 720Gln Ser His Thr
Ile Cys Thr Arg Ser Asp Trp Thr Gly Leu Thr Asn 725
730 735Cys Val Glu Lys Thr Ile Thr Asp Asp Lys
Val Ile Ala Ser Leu Thr 740 745
750Lys Thr Asp Ile Ser Gly Asn Val Asp Leu Ala Asp His Ala His Leu
755 760 765Asn Leu Thr Gly Leu Ala Thr
Leu Asn Gly Asn Leu Ser Ala Asn Gly 770 775
780Asp Thr Arg Tyr Thr Val Ser His Asn Ala Thr Gln Asn Gly Asn
Leu785 790 795 800Ser Leu
Val Gly Asn Ala Gln Ala Thr Phe Asn Gln Ala Thr Leu Asn
805 810 815Gly Asn Thr Ser Ala Ser Gly
Asn Ala Ser Phe Asn Leu Ser Asp His 820 825
830Ala Val Gln Asn Gly Ser Leu Thr Leu Ser Gly Asn Ala Lys
Ala Asn 835 840 845Val Ser His Ser
Ala Leu Asn Gly Asn Val Ser Leu Ala Asp Lys Ala 850
855 860Val Phe His Phe Glu Ser Ser Arg Phe Thr Gly Gln
Ile Ser Gly Gly865 870 875
880Lys Asp Thr Ala Leu His Leu Lys Asp Ser Glu Trp Thr Leu Pro Ser
885 890 895Gly Thr Glu Leu Gly
Asn Leu Asn Leu Asp Asn Ala Thr Ile Thr Leu 900
905 910Asn Ser Ala Tyr Arg His Asp Ala Ala Gly Ala Gln
Thr Gly Ser Ala 915 920 925Thr Asp
Ala Pro Arg Arg Arg Ser Arg Arg Ser Arg Arg Ser Leu Leu 930
935 940Ser Val Thr Pro Pro Thr Ser Val Glu Ser Arg
Phe Asn Thr Leu Thr945 950 955
960Val Asn Gly Lys Leu Asn Gly Gln Gly Thr Phe Arg Phe Met Ser Glu
965 970 975Leu Phe Gly Tyr
Arg Ser Asp Lys Leu Lys Leu Ala Glu Ser Ser Glu 980
985 990Gly Thr Tyr Thr Leu Ala Val Asn Asn Thr Gly
Asn Glu Pro Ala Ser 995 1000
1005Leu Glu Gln Leu Thr Val Val Glu Gly Lys Asp Asn Lys Pro Leu Ser
1010 1015 1020Glu Asn Leu Asn Phe Thr Leu
Gln Asn Glu His Val Asp Ala Gly Ala1025 1030
1035 1040Trp Arg Tyr Gln Leu Ile Arg Lys Asp Gly Glu Phe
Arg Leu His Asn 1045 1050
1055Pro Val Lys Glu Gln Glu Leu Ser Asp Lys Leu Gly Lys Ala Glu Ala
1060 1065 1070Lys Lys Gln Ala Glu Lys
Asp Asn Ala Gln Ser Leu Asp Ala Leu Ile 1075 1080
1085Ala Ala Gly Arg Asp Ala Val Glu Lys Thr Glu Ser Val Ala
Glu Pro 1090 1095 1100Ala Arg Gln Ala
Gly Gly Glu Asn Val Gly Ile Met Gln Ala Glu Glu1105 1110
1115 1120Glu Lys Lys Arg Val Gln Ala Asp Lys
Asp Thr Ala Leu Ala Lys Gln 1125 1130
1135Arg Glu Ala Glu Thr Arg Pro Ala Thr Thr Ala Phe Pro Arg Ala
Arg 1140 1145 1150Arg Ala Arg
Arg Asp Leu Pro Gln Leu Gln Pro Gln Pro Gln Pro Gln 1155
1160 1165Pro Gln Arg Asp Leu Ile Ser Arg Tyr Ala Asn
Ser Gly Leu Ser Glu 1170 1175 1180Phe
Ser Ala Thr Leu Asn Ser Val Phe Ala Val Gln Asp Glu Leu Asp1185
1190 1195 1200Arg Val Phe Ala Glu Asp
Arg Arg Asn Ala Val Trp Thr Ser Gly Ile 1205
1210 1215Arg Asp Thr Lys His Tyr Arg Ser Gln Asp Phe Arg
Ala Tyr Arg Gln 1220 1225
1230Gln Thr Asp Leu Arg Gln Ile Gly Met Gln Lys Asn Leu Gly Ser Gly
1235 1240 1245Arg Val Gly Ile Leu Phe Ser
His Asn Arg Thr Glu Asn Thr Phe Asp 1250 1255
1260Asp Gly Ile Gly Asn Ser Ala Arg Leu Ala His Gly Ala Val Phe
Gly1265 1270 1275 1280Gln
Tyr Gly Ile Asp Arg Phe Tyr Ile Gly Ile Ser Ala Gly Ala Gly
1285 1290 1295Phe Ser Ser Gly Ser Leu Ser
Asp Gly Ile Gly Gly Lys Ile Arg Arg 1300 1305
1310Arg Val Leu His Tyr Gly Ile Gln Ala Arg Tyr Arg Ala Gly
Phe Gly 1315 1320 1325Gly Phe Gly
Ile Glu Pro His Ile Gly Ala Thr Arg Tyr Phe Val Gln 1330
1335 1340Lys Ala Asp Tyr Arg Tyr Glu Asn Val Asn Ile Ala
Thr Pro Gly Leu1345 1350 1355
1360Ala Phe Asn Arg Tyr Arg Ala Gly Ile Lys Ala Asp Tyr Ser Phe Lys
1365 1370 1375Pro Ala Gln His Ile
Ser Ile Thr Pro Tyr Leu Ser Leu Ser Tyr Thr 1380
1385 1390Asp Ala Ala Ser Gly Lys Val Arg Thr Arg Val Asn
Thr Ala Val Leu 1395 1400 1405Ala
Gln Asp Phe Gly Lys Thr Arg Ser Ala Glu Trp Gly Val Asn Ala 1410
1415 1420Glu Ile Lys Gly Phe Thr Leu Ser Leu His
Ala Ala Ala Ala Lys Gly1425 1430 1435
1440Pro Gln Leu Glu Ala Gln His Ser Ala Gly Ile Lys Leu Gly Tyr
Arg 1445 1450
1455Trp14797PRTNeisseria meningitidis 14Met Lys Leu Lys Gln Ile Ala Ser
Ala Leu Met Met Leu Gly Ile Ser1 5 10
15Pro Leu Ala Leu Ala Asp Phe Thr Ile Gln Asp Ile Arg Val
Glu Gly 20 25 30Leu Gln Arg
Thr Glu Pro Ser Thr Val Phe Asn Tyr Leu Pro Val Lys 35
40 45Val Gly Asp Thr Tyr Asn Asp Thr His Gly Ser
Ala Ile Ile Lys Ser 50 55 60Leu Tyr
Ala Thr Gly Phe Phe Asp Asp Val Arg Val Glu Thr Ala Asp65
70 75 80Gly Gln Leu Leu Leu Thr Val
Ile Glu Arg Pro Thr Ile Gly Ser Leu 85 90
95Asn Ile Thr Gly Ala Lys Met Leu Gln Asn Asp Ala Ile
Lys Lys Asn 100 105 110Leu Glu
Ser Phe Gly Leu Ala Gln Ser Gln Tyr Phe Asn Gln Ala Thr 115
120 125Leu Asn Gln Ala Val Ala Gly Leu Lys Glu
Glu Tyr Leu Gly Arg Gly 130 135 140Lys
Leu Asn Ile Gln Ile Thr Pro Lys Val Thr Lys Leu Ala Arg Asn145
150 155 160Arg Val Asp Ile Asp Ile
Thr Ile Asp Glu Gly Lys Ser Ala Lys Ile 165
170 175Thr Asp Ile Glu Phe Glu Gly Asn Gln Val Tyr Ser
Asp Arg Lys Leu 180 185 190Met
Arg Gln Met Ser Leu Thr Glu Gly Gly Ile Trp Thr Trp Leu Thr 195
200 205Arg Ser Asn Gln Phe Asn Glu Gln Lys
Phe Ala Gln Asp Met Glu Lys 210 215
220Val Thr Asp Phe Tyr Gln Asn Asn Gly Tyr Phe Asp Phe Arg Ile Leu225
230 235 240Asp Thr Asp Ile
Gln Thr Asn Glu Asp Lys Thr Lys Gln Thr Ile Lys 245
250 255Ile Thr Val His Glu Gly Gly Arg Phe Arg
Trp Gly Lys Val Ser Ile 260 265
270Glu Gly Asp Thr Asn Glu Val Pro Lys Ala Glu Leu Glu Lys Leu Leu
275 280 285Thr Met Lys Pro Gly Lys Trp
Tyr Glu Arg Gln Gln Met Thr Ala Val 290 295
300Leu Gly Glu Ile Gln Asn Arg Met Gly Ser Ala Gly Tyr Ala Tyr
Ser305 310 315 320Glu Ile
Ser Val Gln Pro Leu Pro Asn Ala Glu Thr Lys Thr Val Asp
325 330 335Phe Val Leu His Ile Glu Pro
Gly Arg Lys Ile Tyr Val Asn Glu Ile 340 345
350His Ile Thr Gly Asn Asn Lys Thr Arg Asp Glu Val Val Arg
Arg Glu 355 360 365Leu Arg Gln Met
Glu Ser Ala Pro Tyr Asp Thr Ser Lys Leu Gln Arg 370
375 380Ser Lys Glu Arg Val Glu Leu Leu Gly Tyr Phe Asp
Asn Val Gln Phe385 390 395
400Asp Ala Val Pro Leu Ala Gly Thr Pro Asp Lys Val Asp Leu Asn Met
405 410 415Ser Leu Thr Glu Arg
Ser Thr Gly Ser Leu Asp Leu Ser Ala Gly Trp 420
425 430Val Gln Asp Thr Gly Leu Val Met Ser Ala Gly Val
Ser Gln Asp Asn 435 440 445Leu Phe
Gly Thr Gly Lys Ser Ala Ala Leu Arg Ala Ser Arg Ser Lys 450
455 460Thr Thr Leu Asn Gly Ser Leu Ser Phe Thr Asp
Pro Tyr Phe Thr Ala465 470 475
480Asp Gly Val Ser Leu Gly Tyr Asp Val Tyr Gly Lys Ala Phe Asp Pro
485 490 495Arg Lys Ala Ser
Thr Ser Ile Lys Gln Tyr Lys Thr Thr Thr Ala Gly 500
505 510Ala Gly Ile Arg Met Ser Val Pro Val Thr Glu
Tyr Asp Arg Val Asn 515 520 525Phe
Gly Leu Val Ala Glu His Leu Thr Val Asn Thr Tyr Asn Lys Ala 530
535 540Pro Lys His Tyr Ala Asp Phe Ile Lys Lys
Tyr Gly Lys Thr Asp Gly545 550 555
560Thr Asp Gly Ser Phe Lys Gly Trp Leu Tyr Lys Gly Thr Val Gly
Trp 565 570 575Gly Arg Asn
Lys Thr Asp Ser Ala Leu Trp Pro Thr Arg Gly Tyr Leu 580
585 590Thr Gly Val Asn Ala Glu Ile Ala Leu Pro
Gly Ser Lys Leu Gln Tyr 595 600
605Tyr Ser Ala Thr His Asn Gln Thr Trp Phe Phe Pro Leu Ser Lys Thr 610
615 620Phe Thr Leu Met Leu Gly Gly Glu
Val Gly Ile Ala Gly Gly Tyr Gly625 630
635 640Arg Thr Lys Glu Ile Pro Phe Phe Glu Asn Phe Tyr
Gly Gly Gly Leu 645 650
655Gly Ser Val Arg Gly Tyr Glu Ser Gly Thr Leu Gly Pro Lys Val Tyr
660 665 670Asp Glu Tyr Gly Glu Lys
Ile Ser Tyr Gly Gly Asn Lys Lys Ala Asn 675 680
685Val Ser Ala Glu Leu Leu Phe Pro Met Pro Gly Ala Lys Asp
Ala Arg 690 695 700Thr Val Arg Leu Ser
Leu Phe Ala Asp Ala Gly Ser Val Trp Asp Gly705 710
715 720Lys Thr Tyr Asp Asp Asn Ser Ser Ser Ala
Thr Gly Gly Arg Val Gln 725 730
735Asn Ile Tyr Gly Ala Gly Asn Thr His Lys Ser Thr Phe Thr Asn Glu
740 745 750Leu Arg Tyr Ser Ala
Gly Gly Ala Val Thr Trp Leu Ser Pro Leu Gly 755
760 765Pro Met Lys Phe Ser Tyr Ala Tyr Pro Leu Lys Lys
Lys Pro Glu Asp 770 775 780Glu Ile Gln
Arg Phe Gln Phe Gln Leu Gly Thr Thr Phe785 790
795156PRTArtificial SequenceLinker 15Gly Ser Gly Gly Gly Gly1
5168PRTArtificial SequenceLinker 16Gly Ser Gly Ser Gly Gly Gly
Gly1 5176PRTArtificial SequencePoly-histidine tag 17His His
His His His His1 5182376DNANeisseria meningitidis
18atgaaaccat tacaaatgct ccctatcgcc gcgctggtcg gcagtatttt cggcaatccg
60gtcttggcag cagatgaagc tgcaactgaa accacacccg ttaaggcaga gataaaagca
120gtgcgcgtta aaggtcagcg caatgcgcct gcggctgtgg aacgcgtcaa ccttaaccgt
180atcaaacaag aaatgatacg cgacaataaa gacttggtgc gctattccac cgatgtcggc
240ttgagcgaca gcggccgcca tcaaaaaggc tttgctgttc gcggcgtgga aggcaaccgt
300gtcggcgtga gcatagacgg tgtaaacctg cctgattctg aagaaaactc gctgtacgcc
360cgttatggca acttcaacag ctcgcgtttg tctatcgacc ccgaactcgt gcgcaacatc
420gaaatcgtga agggcgcaga ctctttcaat accggcagtg gtgcattggg cggcggtgtg
480aattaccaaa cgctgcaagg ccgtgatttg ctgttggacg acaggcaatt cggcgtgatg
540atgaaaaacg gttacagcac gcgtaaccgt gaatggacaa atactctcgg tttcggtgtg
600agtaacgacc gcgtggatgc tgctttgctg tattcgcaac gtcgcggtca tgaaaccgaa
660agcgcgggaa accgaggcta tgctgtggaa ggggaaggca gtggcgcgaa tatccgtggt
720tcggcacgcg gtatccctga ttcgtccaaa cacaaatacc acagcttttt gggtaagatt
780gcttaccaaa ttaacgataa ccaccgcatc ggcgcatcgc ttaacggcca gcagggacat
840aattacacgg ttgaagagtc ttataacctg accgcttctt cctggcgcga agccgatgac
900gtaaacagac ggcgcaatgc caacctcttt tacgaatgga tgcctgattc aaattggttg
960tcgtctttga aggcggactt cgattatcag aaaaccaaag tggcggcggt taacaacaaa
1020ggctcgttcc cgatggatta ttccacctgg acgcgcaact ataatcagaa ggatttggac
1080gaaatataca accgcagcat ggacacccga ttcaaacgtt ttactttgcg tttggacagc
1140catccgttgc aactcggggg ggggcgacac cgcctgtcgt ttaaaacttt cgtcagccgc
1200cgtgattttg aaaacctaaa ccgcgacgat tattacttca gcggccgtgt tgttcgaacc
1260accagcagta tccagcatcc ggtgaaaacc accaactacg gtttctcact gtctgaccaa
1320attcaatgga acgacgtgtt cagtagccgc gcaggtatcc gttacgacca caccaaaatg
1380acgcctcagg aattgaatgc cgagtgtcat gcttgtgaca aaacaccacc tgcagccaac
1440acttataaag gctggagcgg ttttgtcggc ttggcggcgc aactgaatca ggcttggcat
1500gtcggttacg acattacttc cggctaccgc gtccccaatg cgtccgaagt gtatttcacc
1560tacaaccacg gttcgggtaa ttggctgcct aatcccaacc tgaaagccga gcgcagcacc
1620acccacaccc tgtctctgca aggccgcagc gaaaaaggca tgctggatgc caacctgtat
1680caaagcaatt accgcaattt cctgtctgaa gagcagaagc tgaccaccag cggcactccc
1740ggctgtactg aggaaaatgc ttactacggt atatgcagcg acccctacaa agaaaaactg
1800gattggcaga tgaaaaatat cgacaaggcc agaatccgcg gtatcgagct gacaggccgt
1860ctgaatgtgg acaaagtagc gtcttttgtt cctgagggtt ggaaactgtt cggctcgctg
1920ggttatgcga aaagcaaact gtcgggcgac aacagcctgc tgtccacaca gccgctgaaa
1980gtgattgccg gtatcgacta tgaaagtccg agcgaaaaat ggggcgtatt ctcccgcctg
2040acctatctgg gcgcgaaaaa ggccaaagat gcgcagtaca ccgtttatga aaacaagggc
2100tggggtacgc ctttgcagaa aaaggtaaaa gattacccgt ggctgaacaa gtcggcttat
2160gtgtttgata tgtacggctt ctacaaaccg gctaaaaacc tgactttgcg tgcaggcgta
2220tataatgtgt tcaaccgcaa atacaccact tgggattccc tgcgcggcct gtatagctac
2280agcaccacca actcggtcga ccgcgatggc aaaggcttag accgctaccg cgccccaagc
2340cgtaattacg ccgtatcgct ggaatggaag ttttaa
237619791PRTNeisseria meningitidis 19Met Lys Pro Leu Gln Met Leu Pro Ile
Ala Ala Leu Val Gly Ser Ile1 5 10
15Phe Gly Asn Pro Val Leu Ala Ala Asp Glu Ala Ala Thr Glu Thr
Thr 20 25 30Pro Val Lys Ala
Glu Ile Lys Ala Val Arg Val Lys Gly Gln Arg Asn 35
40 45Ala Pro Ala Ala Val Glu Arg Val Asn Leu Asn Arg
Ile Lys Gln Glu 50 55 60Met Ile Arg
Asp Asn Lys Asp Leu Val Arg Tyr Ser Thr Asp Val Gly65 70
75 80Leu Ser Asp Ser Gly Arg His Gln
Lys Gly Phe Ala Val Arg Gly Val 85 90
95Glu Gly Asn Arg Val Gly Val Ser Ile Asp Gly Val Asn Leu
Pro Asp 100 105 110Ser Glu Glu
Asn Ser Leu Tyr Ala Arg Tyr Gly Asn Phe Asn Ser Ser 115
120 125Arg Leu Ser Ile Asp Pro Glu Leu Val Arg Asn
Ile Glu Ile Val Lys 130 135 140Gly Ala
Asp Ser Phe Asn Thr Gly Ser Gly Ala Leu Gly Gly Gly Val145
150 155 160Asn Tyr Gln Thr Leu Gln Gly
Arg Asp Leu Leu Leu Asp Asp Arg Gln 165
170 175Phe Gly Val Met Met Lys Asn Gly Tyr Ser Thr Arg
Asn Arg Glu Trp 180 185 190Thr
Asn Thr Leu Gly Phe Gly Val Ser Asn Asp Arg Val Asp Ala Ala 195
200 205Leu Leu Tyr Ser Gln Arg Arg Gly His
Glu Thr Glu Ser Ala Gly Asn 210 215
220Arg Gly Tyr Ala Val Glu Gly Glu Gly Ser Gly Ala Asn Ile Arg Gly225
230 235 240Ser Ala Arg Gly
Ile Pro Asp Ser Ser Lys His Lys Tyr His Ser Phe 245
250 255Leu Gly Lys Ile Ala Tyr Gln Ile Asn Asp
Asn His Arg Ile Gly Ala 260 265
270Ser Leu Asn Gly Gln Gln Gly His Asn Tyr Thr Val Glu Glu Ser Tyr
275 280 285Asn Leu Thr Ala Ser Ser Trp
Arg Glu Ala Asp Asp Val Asn Arg Arg 290 295
300Arg Asn Ala Asn Leu Phe Tyr Glu Trp Met Pro Asp Ser Asn Trp
Leu305 310 315 320Ser Ser
Leu Lys Ala Asp Phe Asp Tyr Gln Lys Thr Lys Val Ala Ala
325 330 335Val Asn Asn Lys Gly Ser Phe
Pro Met Asp Tyr Ser Thr Trp Thr Arg 340 345
350Asn Tyr Asn Gln Lys Asp Leu Asp Glu Ile Tyr Asn Arg Ser
Met Asp 355 360 365Thr Arg Phe Lys
Arg Phe Thr Leu Arg Leu Asp Ser His Pro Leu Gln 370
375 380Leu Gly Gly Gly Arg His Arg Leu Ser Phe Lys Thr
Phe Val Ser Arg385 390 395
400Arg Asp Phe Glu Asn Leu Asn Arg Asp Asp Tyr Tyr Phe Ser Gly Arg
405 410 415Val Val Arg Thr Thr
Ser Ser Ile Gln His Pro Val Lys Thr Thr Asn 420
425 430Tyr Gly Phe Ser Leu Ser Asp Gln Ile Gln Trp Asn
Asp Val Phe Ser 435 440 445Ser Arg
Ala Gly Ile Arg Tyr Asp His Thr Lys Met Thr Pro Gln Glu 450
455 460Leu Asn Ala Glu Cys His Ala Cys Asp Lys Thr
Pro Pro Ala Ala Asn465 470 475
480Thr Tyr Lys Gly Trp Ser Gly Phe Val Gly Leu Ala Ala Gln Leu Asn
485 490 495Gln Ala Trp His
Val Gly Tyr Asp Ile Thr Ser Gly Tyr Arg Val Pro 500
505 510Asn Ala Ser Glu Val Tyr Phe Thr Tyr Asn His
Gly Ser Gly Asn Trp 515 520 525Leu
Pro Asn Pro Asn Leu Lys Ala Glu Arg Ser Thr Thr His Thr Leu 530
535 540Ser Leu Gln Gly Arg Ser Glu Lys Gly Met
Leu Asp Ala Asn Leu Tyr545 550 555
560Gln Ser Asn Tyr Arg Asn Phe Leu Ser Glu Glu Gln Lys Leu Thr
Thr 565 570 575Ser Gly Thr
Pro Gly Cys Thr Glu Glu Asn Ala Tyr Tyr Gly Ile Cys 580
585 590Ser Asp Pro Tyr Lys Glu Lys Leu Asp Trp
Gln Met Lys Asn Ile Asp 595 600
605Lys Ala Arg Ile Arg Gly Ile Glu Leu Thr Gly Arg Leu Asn Val Asp 610
615 620Lys Val Ala Ser Phe Val Pro Glu
Gly Trp Lys Leu Phe Gly Ser Leu625 630
635 640Gly Tyr Ala Lys Ser Lys Leu Ser Gly Asp Asn Ser
Leu Leu Ser Thr 645 650
655Gln Pro Leu Lys Val Ile Ala Gly Ile Asp Tyr Glu Ser Pro Ser Glu
660 665 670Lys Trp Gly Val Phe Ser
Arg Leu Thr Tyr Leu Gly Ala Lys Lys Ala 675 680
685Lys Asp Ala Gln Tyr Thr Val Tyr Glu Asn Lys Gly Trp Gly
Thr Pro 690 695 700Leu Gln Lys Lys Val
Lys Asp Tyr Pro Trp Leu Asn Lys Ser Ala Tyr705 710
715 720Val Phe Asp Met Tyr Gly Phe Tyr Lys Pro
Ala Lys Asn Leu Thr Leu 725 730
735Arg Ala Gly Val Tyr Asn Val Phe Asn Arg Lys Tyr Thr Thr Trp Asp
740 745 750Ser Leu Arg Gly Leu
Tyr Ser Tyr Ser Thr Thr Asn Ser Val Asp Arg 755
760 765Asp Gly Lys Gly Leu Asp Arg Tyr Arg Ala Pro Ser
Arg Asn Tyr Ala 770 775 780Val Ser Leu
Glu Trp Lys Phe785 79020147PRTNeisseria meningitidis
20Ala Asp Glu Ala Ala Thr Glu Thr Thr Pro Val Lys Ala Glu Ile Lys1
5 10 15Ala Val Arg Val Lys Gly
Gln Arg Asn Ala Pro Ala Ala Val Glu Arg 20 25
30Val Asn Leu Asn Arg Ile Lys Gln Glu Met Ile Arg Asp
Asn Lys Asp 35 40 45Leu Val Arg
Tyr Ser Thr Asp Val Gly Leu Ser Asp Ser Gly Arg His 50
55 60Gln Lys Gly Phe Ala Val Arg Gly Val Glu Gly Asn
Arg Val Gly Val65 70 75
80Ser Ile Asp Gly Val Asn Leu Pro Asp Ser Glu Glu Asn Ser Leu Tyr
85 90 95Ala Arg Tyr Gly Asn Phe
Asn Ser Ser Arg Leu Ser Ile Asp Pro Glu 100
105 110Leu Val Arg Asn Ile Glu Ile Val Lys Gly Ala Asp
Ser Phe Asn Thr 115 120 125Gly Ser
Gly Ala Leu Gly Gly Gly Val Asn Tyr Gln Thr Leu Gln Gly 130
135 140Arg Asp Leu14521621PRTNeisseria meningitidis
21Leu Leu Asp Asp Arg Gln Phe Gly Val Met Met Lys Asn Gly Tyr Ser1
5 10 15Thr Arg Asn Arg Glu Trp
Thr Asn Thr Leu Gly Phe Gly Val Ser Asn 20 25
30Asp Arg Val Asp Ala Ala Leu Leu Tyr Ser Gln Arg Arg
Gly His Glu 35 40 45Thr Glu Ser
Ala Gly Asn Arg Gly Tyr Ala Val Glu Gly Glu Gly Ser 50
55 60Gly Ala Asn Ile Arg Gly Ser Ala Arg Gly Ile Pro
Asp Ser Ser Lys65 70 75
80His Lys Tyr His Ser Phe Leu Gly Lys Ile Ala Tyr Gln Ile Asn Asp
85 90 95Asn His Arg Ile Gly Ala
Ser Leu Asn Gly Gln Gln Gly His Asn Tyr 100
105 110Thr Val Glu Glu Ser Tyr Asn Leu Thr Ala Ser Ser
Trp Arg Glu Ala 115 120 125Asp Asp
Val Asn Arg Arg Arg Asn Ala Asn Leu Phe Tyr Glu Trp Met 130
135 140Pro Asp Ser Asn Trp Leu Ser Ser Leu Lys Ala
Asp Phe Asp Tyr Gln145 150 155
160Lys Thr Lys Val Ala Ala Val Asn Asn Lys Gly Ser Phe Pro Met Asp
165 170 175Tyr Ser Thr Trp
Thr Arg Asn Tyr Asn Gln Lys Asp Leu Asp Glu Ile 180
185 190Tyr Asn Arg Ser Met Asp Thr Arg Phe Lys Arg
Phe Thr Leu Arg Leu 195 200 205Asp
Ser His Pro Leu Gln Leu Gly Gly Gly Arg His Arg Leu Ser Phe 210
215 220Lys Thr Phe Val Ser Arg Arg Asp Phe Glu
Asn Leu Asn Arg Asp Asp225 230 235
240Tyr Tyr Phe Ser Gly Arg Val Val Arg Thr Thr Ser Ser Ile Gln
His 245 250 255Pro Val Lys
Thr Thr Asn Tyr Gly Phe Ser Leu Ser Asp Gln Ile Gln 260
265 270Trp Asn Asp Val Phe Ser Ser Arg Ala Gly
Ile Arg Tyr Asp His Thr 275 280
285Lys Met Thr Pro Gln Glu Leu Asn Ala Glu Cys His Ala Cys Asp Lys 290
295 300Thr Pro Pro Ala Ala Asn Thr Tyr
Lys Gly Trp Ser Gly Phe Val Gly305 310
315 320Leu Ala Ala Gln Leu Asn Gln Ala Trp His Val Gly
Tyr Asp Ile Thr 325 330
335Ser Gly Tyr Arg Val Pro Asn Ala Ser Glu Val Tyr Phe Thr Tyr Asn
340 345 350His Gly Ser Gly Asn Trp
Leu Pro Asn Pro Asn Leu Lys Ala Glu Arg 355 360
365Ser Thr Thr His Thr Leu Ser Leu Gln Gly Arg Ser Glu Lys
Gly Met 370 375 380Leu Asp Ala Asn Leu
Tyr Gln Ser Asn Tyr Arg Asn Phe Leu Ser Glu385 390
395 400Glu Gln Lys Leu Thr Thr Ser Gly Thr Pro
Gly Cys Thr Glu Glu Asn 405 410
415Ala Tyr Tyr Gly Ile Cys Ser Asp Pro Tyr Lys Glu Lys Leu Asp Trp
420 425 430Gln Met Lys Asn Ile
Asp Lys Ala Arg Ile Arg Gly Ile Glu Leu Thr 435
440 445Gly Arg Leu Asn Val Asp Lys Val Ala Ser Phe Val
Pro Glu Gly Trp 450 455 460Lys Leu Phe
Gly Ser Leu Gly Tyr Ala Lys Ser Lys Leu Ser Gly Asp465
470 475 480Asn Ser Leu Leu Ser Thr Gln
Pro Leu Lys Val Ile Ala Gly Ile Asp 485
490 495Tyr Glu Ser Pro Ser Glu Lys Trp Gly Val Phe Ser
Arg Leu Thr Tyr 500 505 510Leu
Gly Ala Lys Lys Ala Lys Asp Ala Gln Tyr Thr Val Tyr Glu Asn 515
520 525Lys Gly Trp Gly Thr Pro Leu Gln Lys
Lys Val Lys Asp Tyr Pro Trp 530 535
540Leu Asn Lys Ser Ala Tyr Val Phe Asp Met Tyr Gly Phe Tyr Lys Pro545
550 555 560Ala Lys Asn Leu
Thr Leu Arg Ala Gly Val Tyr Asn Val Phe Asn Arg 565
570 575Lys Tyr Thr Thr Trp Asp Ser Leu Arg Gly
Leu Tyr Ser Tyr Ser Thr 580 585
590Thr Asn Ser Val Asp Arg Asp Gly Lys Gly Leu Asp Arg Tyr Arg Ala
595 600 605Pro Ser Arg Asn Tyr Ala Val
Ser Leu Glu Trp Lys Phe 610 615
62022768PRTNeisseria meningitidis 22Ala Asp Glu Ala Ala Thr Glu Thr Thr
Pro Val Lys Ala Glu Ile Lys1 5 10
15Ala Val Arg Val Lys Gly Gln Arg Asn Ala Pro Ala Ala Val Glu
Arg 20 25 30Val Asn Leu Asn
Arg Ile Lys Gln Glu Met Ile Arg Asp Asn Lys Asp 35
40 45Leu Val Arg Tyr Ser Thr Asp Val Gly Leu Ser Asp
Ser Gly Arg His 50 55 60Gln Lys Gly
Phe Ala Val Arg Gly Val Glu Gly Asn Arg Val Gly Val65 70
75 80Ser Ile Asp Gly Val Asn Leu Pro
Asp Ser Glu Glu Asn Ser Leu Tyr 85 90
95Ala Arg Tyr Gly Asn Phe Asn Ser Ser Arg Leu Ser Ile Asp
Pro Glu 100 105 110Leu Val Arg
Asn Ile Glu Ile Val Lys Gly Ala Asp Ser Phe Asn Thr 115
120 125Gly Ser Gly Ala Leu Gly Gly Gly Val Asn Tyr
Gln Thr Leu Gln Gly 130 135 140Arg Asp
Leu Leu Leu Asp Asp Arg Gln Phe Gly Val Met Met Lys Asn145
150 155 160Gly Tyr Ser Thr Arg Asn Arg
Glu Trp Thr Asn Thr Leu Gly Phe Gly 165
170 175Val Ser Asn Asp Arg Val Asp Ala Ala Leu Leu Tyr
Ser Gln Arg Arg 180 185 190Gly
His Glu Thr Glu Ser Ala Gly Asn Arg Gly Tyr Ala Val Glu Gly 195
200 205Glu Gly Ser Gly Ala Asn Ile Arg Gly
Ser Ala Arg Gly Ile Pro Asp 210 215
220Ser Ser Lys His Lys Tyr His Ser Phe Leu Gly Lys Ile Ala Tyr Gln225
230 235 240Ile Asn Asp Asn
His Arg Ile Gly Ala Ser Leu Asn Gly Gln Gln Gly 245
250 255His Asn Tyr Thr Val Glu Glu Ser Tyr Asn
Leu Thr Ala Ser Ser Trp 260 265
270Arg Glu Ala Asp Asp Val Asn Arg Arg Arg Asn Ala Asn Leu Phe Tyr
275 280 285Glu Trp Met Pro Asp Ser Asn
Trp Leu Ser Ser Leu Lys Ala Asp Phe 290 295
300Asp Tyr Gln Lys Thr Lys Val Ala Ala Val Asn Asn Lys Gly Ser
Phe305 310 315 320Pro Met
Asp Tyr Ser Thr Trp Thr Arg Asn Tyr Asn Gln Lys Asp Leu
325 330 335Asp Glu Ile Tyr Asn Arg Ser
Met Asp Thr Arg Phe Lys Arg Phe Thr 340 345
350Leu Arg Leu Asp Ser His Pro Leu Gln Leu Gly Gly Gly Arg
His Arg 355 360 365Leu Ser Phe Lys
Thr Phe Val Ser Arg Arg Asp Phe Glu Asn Leu Asn 370
375 380Arg Asp Asp Tyr Tyr Phe Ser Gly Arg Val Val Arg
Thr Thr Ser Ser385 390 395
400Ile Gln His Pro Val Lys Thr Thr Asn Tyr Gly Phe Ser Leu Ser Asp
405 410 415Gln Ile Gln Trp Asn
Asp Val Phe Ser Ser Arg Ala Gly Ile Arg Tyr 420
425 430Asp His Thr Lys Met Thr Pro Gln Glu Leu Asn Ala
Glu Cys His Ala 435 440 445Cys Asp
Lys Thr Pro Pro Ala Ala Asn Thr Tyr Lys Gly Trp Ser Gly 450
455 460Phe Val Gly Leu Ala Ala Gln Leu Asn Gln Ala
Trp His Val Gly Tyr465 470 475
480Asp Ile Thr Ser Gly Tyr Arg Val Pro Asn Ala Ser Glu Val Tyr Phe
485 490 495Thr Tyr Asn His
Gly Ser Gly Asn Trp Leu Pro Asn Pro Asn Leu Lys 500
505 510Ala Glu Arg Ser Thr Thr His Thr Leu Ser Leu
Gln Gly Arg Ser Glu 515 520 525Lys
Gly Met Leu Asp Ala Asn Leu Tyr Gln Ser Asn Tyr Arg Asn Phe 530
535 540Leu Ser Glu Glu Gln Lys Leu Thr Thr Ser
Gly Thr Pro Gly Cys Thr545 550 555
560Glu Glu Asn Ala Tyr Tyr Gly Ile Cys Ser Asp Pro Tyr Lys Glu
Lys 565 570 575Leu Asp Trp
Gln Met Lys Asn Ile Asp Lys Ala Arg Ile Arg Gly Ile 580
585 590Glu Leu Thr Gly Arg Leu Asn Val Asp Lys
Val Ala Ser Phe Val Pro 595 600
605Glu Gly Trp Lys Leu Phe Gly Ser Leu Gly Tyr Ala Lys Ser Lys Leu 610
615 620Ser Gly Asp Asn Ser Leu Leu Ser
Thr Gln Pro Leu Lys Val Ile Ala625 630
635 640Gly Ile Asp Tyr Glu Ser Pro Ser Glu Lys Trp Gly
Val Phe Ser Arg 645 650
655Leu Thr Tyr Leu Gly Ala Lys Lys Ala Lys Asp Ala Gln Tyr Thr Val
660 665 670Tyr Glu Asn Lys Gly Trp
Gly Thr Pro Leu Gln Lys Lys Val Lys Asp 675 680
685Tyr Pro Trp Leu Asn Lys Ser Ala Tyr Val Phe Asp Met Tyr
Gly Phe 690 695 700Tyr Lys Pro Ala Lys
Asn Leu Thr Leu Arg Ala Gly Val Tyr Asn Val705 710
715 720Phe Asn Arg Lys Tyr Thr Thr Trp Asp Ser
Leu Arg Gly Leu Tyr Ser 725 730
735Tyr Ser Thr Thr Asn Ser Val Asp Arg Asp Gly Lys Gly Leu Asp Arg
740 745 750Tyr Arg Ala Pro Ser
Arg Asn Tyr Ala Val Ser Leu Glu Trp Lys Phe 755
760 76523915PRTNeisseria meningitidis 23Met Gln Gln Gln
His Leu Phe Arg Phe Asn Ile Leu Cys Leu Ser Leu1 5
10 15Met Thr Ala Leu Pro Ala Tyr Ala Glu Asn
Val Gln Ala Gly Gln Ala 20 25
30Gln Glu Lys Gln Leu Asp Thr Ile Gln Val Lys Ala Lys Lys Gln Lys
35 40 45Thr Arg Arg Asp Asn Glu Val Thr
Gly Leu Gly Lys Leu Val Lys Ser 50 55
60Ser Asp Thr Leu Ser Lys Glu Gln Val Leu Asn Ile Arg Asp Leu Thr65
70 75 80Arg Tyr Asp Pro Gly
Ile Ala Val Val Glu Gln Gly Arg Gly Ala Ser 85
90 95Ser Gly Tyr Ser Ile Arg Gly Met Asp Lys Asn
Arg Val Ser Leu Thr 100 105
110Val Asp Gly Val Ser Gln Ile Gln Ser Tyr Thr Ala Gln Ala Ala Leu
115 120 125Gly Gly Thr Arg Thr Ala Gly
Ser Ser Gly Ala Ile Asn Glu Ile Glu 130 135
140Tyr Glu Asn Val Lys Ala Val Glu Ile Ser Lys Gly Ser Asn Ser
Val145 150 155 160Glu Gln
Gly Ser Gly Ala Leu Ala Gly Ser Val Ala Phe Gln Thr Lys
165 170 175Thr Ala Asp Asp Val Ile Gly
Glu Gly Arg Gln Trp Gly Ile Gln Ser 180 185
190Lys Thr Ala Tyr Ser Gly Lys Asn Arg Gly Leu Thr Gln Ser
Ile Ala 195 200 205Leu Ala Gly Arg
Ile Gly Gly Ala Glu Ala Leu Leu Ile His Thr Gly 210
215 220Arg Arg Ala Gly Glu Ile Arg Ala His Glu Asp Ala
Gly Arg Gly Val225 230 235
240Gln Ser Phe Asn Arg Leu Val Pro Val Glu Asp Ser Ser Asn Tyr Ala
245 250 255Tyr Phe Ile Val Lys
Glu Glu Cys Lys Asn Gly Ser Tyr Glu Thr Cys 260
265 270Lys Ala Asn Pro Lys Lys Asp Val Val Gly Lys Asp
Glu Arg Gln Thr 275 280 285Val Ser
Thr Arg Asp Tyr Thr Gly Pro Asn Arg Phe Leu Ala Asp Pro 290
295 300Leu Ser Tyr Glu Ser Arg Ser Trp Leu Phe Arg
Pro Gly Phe Arg Phe305 310 315
320Glu Asn Lys Arg His Tyr Ile Gly Gly Ile Leu Glu His Thr Gln Gln
325 330 335Thr Phe Asp Thr
Arg Asp Met Thr Val Pro Ala Phe Leu Thr Lys Ala 340
345 350Val Phe Asp Ala Asn Lys Lys Gln Ala Gly Ser
Leu Pro Gly Asn Gly 355 360 365Lys
Tyr Ala Gly Asn His Lys Tyr Gly Gly Leu Phe Thr Asn Gly Glu 370
375 380Asn Gly Ala Leu Val Gly Ala Glu Tyr Gly
Thr Gly Val Phe Tyr Asp385 390 395
400Glu Thr His Thr Lys Ser Arg Tyr Gly Leu Glu Tyr Val Tyr Thr
Asn 405 410 415Ala Asp Lys
Asp Thr Trp Ala Asp Tyr Ala Arg Leu Ser Tyr Asp Arg 420
425 430Gln Gly Ile Gly Leu Asp Asn His Phe Gln
Gln Thr His Cys Ser Ala 435 440
445Asp Gly Ser Asp Lys Tyr Cys Arg Pro Ser Ala Asp Lys Pro Phe Ser 450
455 460Tyr Tyr Lys Ser Asp Arg Val Ile
Tyr Gly Glu Ser His Arg Leu Leu465 470
475 480Gln Ala Ala Phe Lys Lys Ser Phe Asp Thr Ala Lys
Ile Arg His Asn 485 490
495Leu Ser Val Asn Leu Gly Phe Asp Arg Phe Gly Ser Asn Leu Arg His
500 505 510Gln Asp Tyr Tyr Tyr Gln
His Ala Asn Arg Ala Tyr Ser Ser Asn Thr 515 520
525Pro Pro Gln Asn Asn Gly Lys Lys Ile Ser Pro Asn Gly Ser
Glu Thr 530 535 540Ser Pro Tyr Trp Val
Thr Ile Gly Arg Gly Asn Val Val Thr Gly Gln545 550
555 560Ile Cys Arg Leu Gly Asn Asn Thr Tyr Thr
Asp Cys Thr Pro Arg Ser 565 570
575Ile Asn Gly Lys Ser Tyr Tyr Ala Ala Val Arg Asp Asn Val Arg Leu
580 585 590Gly Arg Trp Ala Asp
Val Gly Ala Gly Leu Arg Tyr Asp Tyr Arg Ser 595
600 605Thr His Ser Asp Asp Gly Ser Val Ser Thr Gly Thr
His Arg Thr Leu 610 615 620Ser Trp Asn
Ala Gly Ile Val Leu Lys Pro Thr Asp Trp Leu Asp Leu625
630 635 640Thr Tyr Arg Thr Ser Thr Gly
Phe Arg Leu Pro Ser Phe Ala Glu Met 645
650 655Tyr Gly Trp Arg Ala Gly Val Gln Ser Lys Ala Val
Lys Ile Asp Pro 660 665 670Glu
Lys Ser Phe Asn Lys Glu Ala Gly Ile Val Phe Lys Gly Asp Phe 675
680 685Gly Asn Leu Glu Ala Ser Trp Phe Asn
Asn Ala Tyr Arg Asp Leu Ile 690 695
700Val Arg Gly Tyr Glu Ala Gln Ile Lys Asp Gly Lys Glu Glu Ala Lys705
710 715 720Gly Asp Pro Ala
Tyr Leu Asn Ala Gln Ser Ala Arg Ile Thr Gly Ile 725
730 735Asn Ile Leu Gly Lys Ile Asp Trp Asn Gly
Val Trp Asp Lys Leu Pro 740 745
750Glu Gly Trp Tyr Ser Thr Phe Ala Tyr Asn Arg Val Arg Val Arg Asp
755 760 765Ile Lys Lys Arg Ala Asp Arg
Thr Asp Ile Gln Ser His Leu Phe Asp 770 775
780Ala Ile Gln Pro Ser Arg Tyr Val Val Gly Leu Gly Tyr Asp Gln
Pro785 790 795 800Glu Gly
Lys Trp Gly Val Asn Gly Met Leu Thr Tyr Ser Lys Ala Lys
805 810 815Glu Ile Thr Glu Leu Leu Gly
Ser Arg Ala Leu Leu Asn Gly Asn Ser 820 825
830Arg Asn Thr Lys Ala Thr Ala Arg Arg Thr Arg Pro Trp Tyr
Ile Val 835 840 845Asp Val Ser Gly
Tyr Tyr Thr Val Lys Lys His Phe Thr Leu Arg Ala 850
855 860Gly Val Tyr Asn Leu Leu Asn Tyr Arg Tyr Val Thr
Trp Glu Asn Val865 870 875
880Arg Gln Thr Ala Gly Gly Ala Val Asn Gln His Lys Asn Val Gly Val
885 890 895Tyr Asn Arg Tyr Ala
Ala Pro Gly Arg Asn Tyr Thr Phe Ser Leu Glu 900
905 910Met Lys Phe 91524712PRTNeisseria
meningitidis 24Met Asn Asn Pro Leu Val Asn Gln Ala Ala Met Val Leu Pro
Val Phe1 5 10 15Leu Leu
Ser Ala Cys Leu Gly Gly Gly Gly Ser Phe Asp Leu Asp Ser 20
25 30Val Asp Thr Glu Ala Pro Arg Pro Ala
Pro Lys Tyr Gln Asp Val Phe 35 40
45Ser Glu Lys Pro Gln Ala Gln Lys Asp Gln Gly Gly Tyr Gly Phe Ala 50
55 60Met Arg Leu Lys Arg Arg Asn Trp Tyr
Pro Gln Ala Lys Glu Asp Glu65 70 75
80Val Lys Leu Asp Glu Ser Asp Trp Glu Ala Thr Gly Leu Pro
Asp Glu 85 90 95Pro Lys
Glu Leu Pro Lys Arg Gln Lys Ser Val Ile Glu Lys Val Glu 100
105 110Thr Asp Ser Asp Asn Asn Ile Tyr Ser
Ser Pro Tyr Leu Lys Pro Ser 115 120
125Asn His Gln Asn Gly Asn Thr Gly Asn Gly Ile Asn Gln Pro Lys Asn
130 135 140Gln Ala Lys Asp Tyr Glu Asn
Phe Lys Tyr Val Tyr Ser Gly Trp Phe145 150
155 160Tyr Lys His Ala Lys Arg Glu Phe Asn Leu Lys Val
Glu Pro Lys Ser 165 170
175Ala Lys Asn Gly Asp Asp Gly Tyr Ile Phe Tyr His Gly Lys Glu Pro
180 185 190Ser Arg Gln Leu Pro Ala
Ser Gly Lys Ile Thr Tyr Lys Gly Val Trp 195 200
205His Phe Ala Thr Asp Thr Lys Lys Gly Gln Lys Phe Arg Glu
Ile Ile 210 215 220Gln Pro Ser Lys Ser
Gln Gly Asp Arg Tyr Ser Gly Phe Ser Gly Asp225 230
235 240Asp Gly Glu Glu Tyr Ser Asn Lys Asn Lys
Ser Thr Leu Thr Asp Gly 245 250
255Gln Glu Gly Tyr Gly Phe Thr Ser Asn Leu Glu Val Asp Phe His Asn
260 265 270Lys Lys Leu Thr Gly
Lys Leu Ile Arg Asn Asn Ala Asn Thr Asp Asn 275
280 285Asn Gln Ala Thr Thr Thr Gln Tyr Tyr Ser Leu Glu
Ala Gln Val Thr 290 295 300Gly Asn Arg
Phe Asn Gly Lys Ala Thr Ala Thr Asp Lys Pro Gln Gln305
310 315 320Asn Ser Glu Thr Lys Glu His
Pro Phe Val Ser Asp Ser Ser Ser Leu 325
330 335Ser Gly Gly Phe Phe Gly Pro Gln Gly Glu Glu Leu
Gly Phe Arg Phe 340 345 350Leu
Ser Asp Asp Gln Lys Val Ala Val Val Gly Ser Ala Lys Thr Lys 355
360 365Asp Lys Pro Ala Asn Gly Asn Thr Ala
Ala Ala Ser Gly Gly Thr Asp 370 375
380Ala Ala Ala Ser Asn Gly Ala Ala Gly Thr Ser Ser Glu Asn Gly Lys385
390 395 400Leu Thr Thr Val
Leu Asp Ala Val Glu Leu Lys Leu Gly Asp Lys Glu 405
410 415Val Gln Lys Leu Asp Asn Phe Ser Asn Ala
Ala Gln Leu Val Val Asp 420 425
430Gly Ile Met Ile Pro Leu Leu Pro Glu Ala Ser Glu Ser Gly Asn Asn
435 440 445Gln Ala Asn Gln Gly Thr Asn
Gly Gly Thr Ala Phe Thr Arg Lys Phe 450 455
460Asp His Thr Pro Glu Ser Asp Lys Lys Asp Ala Gln Ala Gly Thr
Gln465 470 475 480Thr Asn
Gly Ala Gln Thr Ala Ser Asn Thr Ala Gly Asp Thr Asn Gly
485 490 495Lys Thr Lys Thr Tyr Glu Val
Glu Val Cys Cys Ser Asn Leu Asn Tyr 500 505
510Leu Lys Tyr Gly Met Leu Thr Arg Lys Asn Ser Lys Ser Ala
Met Gln 515 520 525Ala Gly Glu Ser
Ser Ser Gln Ala Asp Ala Lys Thr Glu Gln Val Glu 530
535 540Gln Ser Met Phe Leu Gln Gly Glu Arg Thr Asp Glu
Lys Glu Ile Pro545 550 555
560Ser Glu Gln Asn Ile Val Tyr Arg Gly Ser Trp Tyr Gly Tyr Ile Ala
565 570 575Asn Asp Lys Ser Thr
Ser Trp Ser Gly Asn Ala Ser Asn Ala Thr Ser 580
585 590Gly Asn Arg Ala Glu Phe Thr Val Asn Phe Ala Asp
Lys Lys Ile Thr 595 600 605Gly Thr
Leu Thr Ala Asp Asn Arg Gln Glu Ala Thr Phe Thr Ile Asp 610
615 620Gly Asn Ile Lys Asp Asn Gly Phe Glu Gly Thr
Ala Lys Thr Ala Glu625 630 635
640Ser Gly Phe Asp Leu Asp Gln Ser Asn Thr Thr Arg Thr Pro Lys Ala
645 650 655Tyr Ile Thr Asp
Ala Lys Val Gln Gly Gly Phe Tyr Gly Pro Lys Ala 660
665 670Glu Glu Leu Gly Gly Trp Phe Ala Tyr Pro Gly
Asp Lys Gln Thr Lys 675 680 685Asn
Ala Thr Asn Ala Ser Gly Asn Ser Ser Ala Thr Val Val Phe Gly 690
695 700Ala Lys Arg Gln Gln Pro Val Arg705
71025186PRTNeisseria meningitidis 25Met Asn Met Lys Thr Leu Leu
Ala Leu Ala Val Ser Ala Val Cys Ser1 5 10
15Val Gly Val Ala Gln Ala His Glu His Asn Thr Ile Pro
Lys Gly Ala 20 25 30Ser Ile
Glu Val Lys Val Gln Gln Leu Asp Pro Val Asn Gly Asn Lys 35
40 45Asp Val Gly Thr Val Thr Ile Thr Glu Ser
Asn Tyr Gly Leu Val Phe 50 55 60Thr
Pro Asp Leu Gln Gly Leu Ser Glu Gly Leu His Gly Phe His Ile65
70 75 80His Glu Asn Pro Ser Cys
Glu Pro Lys Glu Lys Glu Gly Lys Leu Thr 85
90 95Ala Gly Leu Gly Ala Gly Gly His Trp Asp Pro Lys
Gly Ala Lys Gln 100 105 110His
Gly Tyr Pro Trp Gln Asp Asp Ala His Leu Gly Asp Leu Pro Ala 115
120 125Leu Thr Val Leu His Asp Gly Thr Ala
Thr Asn Pro Val Leu Ala Pro 130 135
140Arg Leu Lys His Leu Asp Asp Val Arg Gly His Ser Ile Met Ile His145
150 155 160Thr Gly Gly Asp
Asn His Ser Asp His Pro Ala Pro Leu Gly Gly Gly 165
170 175Gly Pro Arg Met Ala Cys Gly Val Ile Lys
180 185
User Contributions:
Comment about this patent or add new information about this topic: